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“Go ahead, be cynical and let fear rule your life. I've got (stuff) to do, worlds to change, 
and it's fun, so I’ll see you later.”
Nicco Miele

ABSTRACT
Gastroesophageal reflux disease (GERD) and sleep problems are common health problems in 
the Western world affecting up to 30% and 33% of the population respectively. GERD is 
associated with decreased quality of life, medication, increased use of health care facilities 
and increased risk of esophageal adenocarcinoma. Sleep problems are linked to mental 
disorders, pain disorders, coronary heart disease, impaired work productivity and increased 
risks of traffic accidents. These two disorders have been shown to be associated and a 
bidirectional association has been suggested. The main focus of this thesis is the link between 
sleep problems and gastroesophageal reflux symptoms (GERS), while also including one
study of the related potential association of obstructive sleep apnea and Barrett´s esophagus. 
In study I we explored prevalence changes, incidence and spontaneous loss of GERS in a 
longitudinal population-based setting using the Nord-Trøndelag health study (HUNT). 
Included in the study were all residents of the county of Nord-Trøndelag, Norway and who 
reported any degree of GERS in 1995-1997 (n=58,869) and in 2006-2009 (n=44,997). Of 
these, 29,610 (61%) responded at both time points with an average of 11 year follow-up. 
Between 1995-1997 and 2006-2009 we found a 30% increase in the prevalence of any 
GERS, a 24% increase in severe GERS and a 49% increase in the prevalence of at least 
weekly GERS. The average annual incidence was 3.07% for any GERS and 0.23% for severe 
GERS, while the annual average spontaneous loss of any GERS were 2.32% and 1.22% 
respectively. 
In study II we used a cross-sectional co-twin control design to analyze the association 
between sleep problems and GERD while controlling for hereditary factors. Included in the 
study were 8,014 same-sexed twins of at least 65 years of age born 1886-1958 identified from 
the Swedish Twin Register. There was a dose-dependent association between sleep problems 
and GERD which remained when only discordant dizygotic twins (one twin has GERD the 
other not) were included in the analysis but this was not seen for monozygotic twins. The 
association between sleep problems and GERD does not seem to be confounded by 
hereditary factors. 
In study III we explored the association between symptoms of obstructive sleep apnea, GERS 
and Barrett’s esophagus in a population-based case-control study from Brisbane, Australia. 
Included in the study were 237 cases of histological confirmed Barrett´s esophagus and 247 
population-controls. No statistically significant association between obstructive sleep apnea 
symptoms and Barrett´s esophagus was observed. 
In study IV we investigated the direction of association between sleep problems and GERS, 
based on the same two previously describe data collections from HUNT (see study I). We 
found that the association between sleep problems and GERS seems to be bidirectional, but 
contrary to what was expected we found a stronger association sleep problems and incident 
GERS than between GERS and incident sleep problems.
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11 INTRODUCTION
Gastroesophageal reflux disease (GERD) and sleep problems are major health problems, 
and the association between them has attracted a great deal of attention over the last decade.
GERD, commonly presenting as acid regurgitations and heartburn, affects 10-30% of the 
adults in the Western world and is a rising health problem in Asia.1 It has been shown that 
frequent GERD is associated with adverse quality of life,2 sickness absence,3 disturbed 
sleep, increased medication use, increased burden for the health care system, all with high 
costs to society.4 Sleep problems are also a common health problem and affect up to 33% of 
the population.5 An association between sleep problems and GERD has been observed, and 
it has been suggested, but not thoroughly studied, that the association is bidirectional.6 The 
following questions then arise: How are these common disorders related? Do sleep 
problems cause GERD or does GERD cause sleep problems? Or is the association 
bidirectional? This thesis aims to increase the knowledge regarding the relationship
between sleep problems and reflux by providing valid measures of changes in prevalence, 
incidence and loss of gastroesophageal reflux symptoms (GERS), studying hereditary 
factors, investigating the wider association between obstructive sleep apnea and Barrett´s 
esophagus (a precursor for adenocarcinoma of the esophagus and for which GERD is the 
main risk factor)7,8 and the direction of the association between sleep problems and GERS.

32 BACKGROUND
2.1 GASTROESOPHAGEAL REFLUX 
2.1.1 Definitions
2.1.1.1 The Montreal definition
According to the Montreal definition gastroesophageal reflux disease (GERD) is the recurrent 
regurgitation of stomach contents into the esophagus which causes troublesome symptoms 
and/or complications.9 The definition further states that characteristic symptoms of GERD are 
heartburn (defined as a burning sensation in the retrosternal area behind the breastbone) and 
regurgitation (defined as the perception of flow of refluxed gastric content into the mouth or 
hypopharynx) and that in clinical practice the patients themselves should determine if their 
symptoms are troublesome. Reflux symptoms that are not perceived as troublesome by the 
patients should not be diagnosed as GERD. The definition further distinguishes between 
manifestations of GERD as symptomatic syndromes and syndromes with esophageal injury.
The first describes patients with symptoms of GERD (not examined with endoscopy) or 
patients with symptoms where no mucosal damage was found during endoscopy. The second 
group of syndromes includes disorders where mucosal injury has been seen during endoscopy 
and includes manifestations of esophagitis, reflux stricture, Barrett´s esophagus and 
esophageal adenocarcinoma. The reason for this distinction is that, in clinical practice, a 
clinician should be able to diagnose GERD with varying amounts of information.9    
The Montreal definition came about as a result of a Delphi process in 2006, i.e. a consensus-
seeking model, including a group of 44 experts from 18 countries with relevant expertise in 
GERD. A working group made a draft of statements which constitute the definition, 
conducted systematic literature reviews and graded the level of evidence to support the 
statements. The larger consensus group voted and statements were altered during a number of 
iterations until consensus was reached. A non-voting chairman led the discussions and the 
voting processes were anonymous, allowing for changes of opinion during the process and in 
order to minimize the influence of the most well-known experts upon the others.9
The Montreal definition has been challenged and the subjective nature of the patient’s 
perception in the decision making process in clinical settings are questioned. It has been 
proposed that the response of patients to proton pump inhibitors (PPIs) should be used as a 
verification of gastroesophageal reflux symptoms (GERS).10 It has also been shown in a 
group of patients with esophagitis verified by upper endoscopy that up to 37% of the patients
did not suffer from heartburn or acid regurgitation, which may indicate that the definition 
might lead to under or over-reporting of GERD.11
4In the studies included in this thesis we have used the term gastroesophageal reflux symptoms 
(GERS) when reflux was assessed by 1-2 questions asking about the intensity or frequency of 
symptoms (studies I, III and IV), and gastroesophageal reflux disease (GERD) when it was 
assessed by a battery of 10 reflux questions asking both about the intensity and frequency of 
symptoms (study II). 
2.1.1.2 pH-monitoring 
In clinical practice, pH-monitoring is also used to objectively detect acidic GERD. A small 
catheter or wireless pH-capsules are inserted and left in the esophagus, approximately 5 cm 
above the proximal lower esophageal sphincter (LES) for a catheter electrode and 6 cm above 
the squamocolumnar junction  for wireless pH-capsules, and the pH-level is usually measured
during 24 or 48 hour surveillance.12 The percentage of time the pH is <4 is measured and a 
cutoff point of 4.2% is suggested to indicate pathological acid reflux.13 But a lower exposure 
time, 3.5% has also shown to correlate well with acidic reflux.14 However, many patients 
with GERS do not show a pH <4 for longer periods, so this method has low sensitivity, and 
should be used together with assessment of symptoms and upper endoscopic investigation.
2.1.1.3 Nocturnal reflux
Nocturnal reflux is GERD that occurs during sleep. It has been suggested that nocturnal 
reflux is a different disease from GERD,15 and that nocturnal reflux is more severe and has a
larger impact on the esophageal mucosa.16,17 In our studies we did not have the ability to 
differentiate between GERD/ GERS and nocturnal reflux. 
2.1.2 Pathophysiology 
In order to study the link between sleep problems and GERD an understanding of the 
functions of the esophagogastric junction is needed. There is a natural intricate barrier in the 
esophagogastric junction that prevents backflow of gastric contents into the esophagus. The 
barrier has three components: the lower esophageal sphincter (LES), the hiatus in the crural 
diaphragm, and the flap valve mechanism which forms a sharp angle between the esophagus 
and the cardia of the stomach, also called the angle of His.18,19 The LES consists of a segment 
of approximately 4 cm of smooth muscles in the distal esophagus. These muscles constitute 
the internal part of the pressure mechanism while the crural diaphragm constitutes the 
external part of the pressure mechanism. It is the constant high pressure which prevents 
backflow of gastric contents. The normal resting pressure of LES is 10 to 35 mm Hg. In a
normal case, hiatus of the crural diaphragm encircles the distal esophagus and the hiatus is 
approximately 2 cm long.19
Gastroesophageal reflux occurs when the reflux barrier is intimidated which most commonly 
happens by: 1) transient lower esophageal sphincter relaxations (TLESRs), 2) anatomic 
5disruption of the reflux barrier, and 3) low resting pressure of the LES.16,19
1) TLESRs are defined as an abrupt decrease in LES pressure compared to the intragastric 
pressure that is not associated with swallowing. The duration of the TLESRs is considered to 
be longer than swallow-induced LES relaxations.20 These relaxations allow us to belch, but 
are also responsible for the majority of reflux episodes both in GERD patients and in healthy 
subjects.20,21
2) Hiatal hernia is an anatomic disruption of the anti-reflux barrier. Typically a hiatal hernia 
occurs when a part of the stomach herniates through the diaphragm, and the pressure 
mechanism between the LES and the surrounding diaphragm is disrupted. When the LES 
relaxes to allow swallowing, acid that has been caught in the hernia sack can flow back into
the esophagus.19 Hiatal hernias are very common among patients with moderate to severe 
reflux and hernia size correlates with severity of esophageal esophagitis.22 However, many 
patients with verified hiatal hernia do not have any reflux symptoms at all.23
3) Low resting pressure of LES was previously believed to be the main factor involved in 
GERD episodes, before the discovery of TLESRs.16 High abdominal pressure can, however,
in combination with lower resting LES pressure, lead to reflux episodes or very low LES 
pressure (0-4  mm Hg) increasing the risk of spontaneous reflux episodes.16,24
2.1.3 Occurrence
GERD is a common disorder which is prevalent worldwide and the prevalence seems to have 
increased over time.25 In 2005 a systematic review of 15 studies concluded that the 
prevalence of GERD was 10-20% in Europe and the USA, and less than 5% in Asia. The 
incidence was 5 per 1000 person years in the populations of UK and USA.26 An update of the 
previous systematic review concluded that the prevalence of GERD was 18.1-27.8% in North 
America, 23.0% in South America, 8.8-25.9% in Europe, 2.5-7.8% in East Asia, 8.7-33.1% 
in the Middle East and 11.6% in Australia.1 In these studies GERD was defined as at least 
weekly symptoms of acid regurgitation or heartburn and assessed by questionnaires or by a 
physician.
2.1.4 Etiology  
2.1.4.1 Heredity
As early as in the 1930s there were reports of familial aggregation of GERS.27 Later studies 
of family members of patients with GERD found a familial aggregation of both GERD and 
Barrett´s esophagus.28,29 Even though these studies controlled for potential confounding 
factors, they could not differ between genetic and environmental factors. Later this was 
accomplished in two large twin studies which used  monozygotic and dizygotic twin-pairs to 
show that the liability of GERD was 31% in a large Swedish twin study,30 and 43% in a large 
twin study from the UK.31 The gene collagen type III alpha 1 has been associated with GERD 
in both men and women, and for men a hereditary association has also been seen with hiatal
6hernia.32
2.1.4.2 Lifestyle factors
Associations between high body mass index (BMI) and GERD have been observed 
repeatedly,33-37 and obesity is seen as one of the strongest risk factors for GERD. Tobacco 
smoking has also been associated with an increased risk of GERD,37,38 while high dietary 
fiber intake and physical exercise seem to be protective.39 The results for alcohol 
consumption and GERD are diverse. Some studies reported that excessive drinking37 or 
drinking spirits was associated with GERD,40  but in other studies no association, regardless 
of type of alcohol were found. 35,39 Low socioeconomic status and low education has also 
been associated with GERS.41,42      
2.1.5 Treatment
GERD is mainly treated with medical therapy or surgery, and lifestyle changes are also 
recommended as a first step to decrease symptoms. These changes include smoking
cessation, weight loss, avoiding food that may trigger reflux episodes such as coffee, 
chocolate, alcohol, citrus fruits, peppermint, carbonated drinks and to sleep with one’s head 
raised off the bed.43 Of these factors, a systematic review found improved pH-profiles or 
symptom decrease only for head off bed elevation and weight loss.44 A recent study from our 
group also found a decrease in GERS after weight-loss and a more efficient effect of reflux 
medication after weight loss.45
2.1.5.1 Medical treatment
The most commonly used drugs for treatment of GERD are proton pump inhibitors (PPI), 
H2-receptor antagonists (H2RA) and antacids. While PPIs and H2RAs decrease the 
production of acid secretion by shutting down the cell pump (PPI) and blocking the signal 
generated by histamine receptors substance (H2RA), antacids neutralize the acid. PPIs have
been reported to be more effective than H2RA in relieving more severe GERS and to be more 
effective at healing esophagitis.43 Low dose PPI, H2RA and antacids can be bought without 
prescription over the counter while a prescription is needed for higher doses.
2.1.5.2 Anti-reflux surgery
Another treatment for severe GERD is anti-reflux surgery where the reflux barrier is partly 
reconstructed by removing any hiatal hernia and wrapping the fundus of the stomach around 
the distal esophagus by means of total fundoplication 360ᵒ  (e.g. Nissen) or partial 
fundoplication (e.g. Toupét).46-48 Both open and laparoscopic approaches have been shown to
be equally effective at decreasing recurrence of esophagitis and heartburn as treatment with 
PPI, and better at treating regurgitations.49,50 The adverse effects of surgery compared to PPI 
use include, apart from risk of surgical complications, higher rates of dysphagia, bloating and
flatulence, since the patient is unable to belch and vomit.49,50 PPIs are therefore recommended 
as initial therapy because of the superior safety but in selected severe cases, if patients are at 
7least partly responsive to medical treatment but intolerant, anti-reflux surgery should be 
considered.43  
2.1.6 Complications of GERD
Complications of GERD includes esophagitis, strictures, Barrett´s esophagus and 
adenocarcinoma of the esophagus,8,9 but progression of GERD is only seen in a small 
proportion of cases.51 Esophagitis is defined endoscopically by visible breaks of the distal 
esophageal mucosa and is seen in less than 50% of patients with typical GERD symptoms.9
Strictures are caused by acidic damage and scarring, and can result in dysphagia. Barrett´s 
esophagus is described in more detail below. Adenocarcinoma of the esophagus is a cancer 
with poor prognosis, with an increasing incidence since the 1970, particularly in white men.52
The ratio between men and women in this cancer is up to 9:1,53,54 and cannot be explained by
the relatively small differences in prevalence between men and women in GERD. 
2.2 BARRETT’S ESOPHAGUS
2.2.1 Definition
Barrett´s esophagus is defined as the presence of a specialized intestinal metaplasia 
(columnar epithelium with goblet cells) replacing the native squamous cell epithelium. 
Barrett’s esophagus is typically occurring in the distal esophagus, but the extent could be 
high.55 The diagnosis is confirmed by biopsies taken from the esophagus by upper 
gastrointestinal endoscopy. 
2.2.2 Occurrence 
The population prevalence of Barrett´s esophagus is difficult to assess as the condition does 
not usually cause any specific symptoms and upper endoscopy is needed for a diagnosis. A 
prevalence study based on endoscopies a random sample of adults living in northern Sweden 
revealed a population prevalence of Barrett´s esophagus as high as 1.6%, although this might 
still be an overestimation due to selection bias.56
2.2.3 Etiology
GERD is the strongest known risk factor for Barrett’s esophagus,57 but high BMI,58
particularly abdominal obesity typically seen in men with high BMI, is also a strong risk 
factor.59 Tobacco smoking has been shown to be associated with increased risk of Barrett’s 
esophagus and the risk increases with number of pack-years (estimated value of life 
consumption of cigarettes).60 Interaction effects between GERD, obesity, smoking and 
increased risks of Barrett´s esophagus have been seen.61
2.3 SLEEP DISTURBANCES
Sleep disturbances are associated with mental disorders, generally poor health, moderately
increased risk of myocardial infarction and decreased health related quality of life.62,63 64
8There are etiological differences for sleep problem/insomnia and obstructive sleep apnea, but 
as they are both sleep disturbances they will be described jointly. 
2.3.1 Definitions
2.3.1.1 Sleep problems 
“Sleep problems” is a widely used term which can cover a number of different disorders and 
is often used differently across studies. In general, sleep problems are often defined as having 
trouble falling asleep, maintaining or experiencing non-restorative sleep. Usually it is 
differentiated from a clinical diagnosis of sleep problems such as primary insomnia and 
symptoms of sleep problems. In this thesis, sleep problems is used as a general term for 
participants reporting trouble falling asleep, having difficulty maintaining sleep (waking up 
too early) or experiencing non-restorative sleep.    
2.3.1.2 Insomnia 
According to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-
IV),65 the criteria for primary insomnia includes having difficulty initiating or maintaining 
sleep or experiencing non-restorative sleep for at least one month. In addition it is also a 
prerequisite that the sleep disturbance has a clinically significant adverse impact on social, 
occupational or other important areas of functioning. In order to give a patient the diagnosis
primary insomnia, the symptoms may not occur exclusively during the course of another 
sleep disorder, exclusively during the course of a mental disorder, or exclusively due to direct 
physiological effects of a substance or a general mental condition.65 In epidemiological 
studies it is often not possible to use the strict diagnoses of insomnia and instead insomnia 
symptoms (usually a combination of symptoms of  trouble falling asleep, maintaining or 
experiencing non-restorative sleep and signs of effects on daily life) is often used. In study IV
we use a proxy for primary insomnia based on insomnia symptoms.
2.3.1.3 Obstructive sleep apnea
Obstructive sleep apnea (OSA) is a chronic condition characterized by recurrent complete or 
partial airway collapse during sleep which often results in disturbed sleep and excessive 
daytime sleepiness.66,67 For a clinical diagnosis of OSA a test with polysomnography (a sleep 
test usually performed in a sleep lab which can measure different activities including brain 
activity, eye movement and breathing patterns during sleep) should be performed. The 
number of complete (apneas) or incomplete (hypneas) breathing stops per hour of sleep is 
then counted and a mean apnea-hypnea score (AHI) number of breathing stops per hour of 
sleep is calculated. A score of ≥5 to <15 is considered mild OSA, a score of ≥15 to <30 
moderate and a score of ≥30/h as severe OSA.66,68
2.3.1.4 Obstructive sleep apnea syndrome 
Obstructive sleep apnea syndrome (OSAS) has a stricter definition than OSA. As well as
fulfilling an AHI score of ≥5, symptoms of daytime sleepiness should also be present.66
92.3.1.5 Symptoms of obstructive sleep apnea
Symptoms of obstructive sleep apnea are clinical symptoms which are often present in 
patients with sleep apnea, such as daytime sleepiness, snorting or gasping, loud snoring or 
breathing stops, choking or struggling for breath. In study III we use symptoms of obstructive 
sleep apnea as a proxy for OSA. 
2.3.2 Occurrence 
2.3.2.1 Sleep problems and insomnia
The prevalence of sleep problems and insomnia varies across studies, often due to the fact 
that sleep problems and insomnia are defined and assessed differently. In a large review the 
prevalence of sleep problems defined as having trouble falling asleep, maintaining or 
experiencing non-restorative sleep was 33%. This figure was 9-15% when the criterion of 
daytime impairment was added, and about 6% when only clinical diagnoses where included;
results were mainly from studies performed in Europe or the US.5 In a recent population-
based Swedish study, the prevalence of sleep problems (defined as having trouble falling 
asleep at least 3-4 times a week or waking up at least 3-4 times per night) was 24.6% and the 
prevalence for insomnia symptoms (defined as having sleep problems and at least moderate 
inference with daytime functioning) was 10.5%. 69 In a Chinese study using a similar 
definition, the prevalence of sleep problems was 6.8%, insomnia symptoms 4.8%, and the 
cumulative incidence of insomnia symptoms was 5.9%.70 In a recent Norwegian study using 
the HUNT data, the prevalence of insomnia symptoms (defined as having difficulty falling 
asleep, waking up repeatedly during the night or waking up too early and unable to go back to 
sleep several times a week, in combination with feeling sleepy during the day several times a 
week) was 7.1% .71
2.3.2.2 Obstructive sleep apnea
The prevalence of mild to moderate OSA (apnea-hypnea score of ≥5 only) is as common as 
27% and 16% in middle aged men and women, respectively. The prevalence of OSAS (OSA 
with apnea-hypnea score of ≥5 in combination with symptoms of daytime sleepiness) is 
estimated to be 2-4% in men and 2-3% in women.66
2.3.3 Etiology
2.3.3.1 Sleep problems and insomnia
Heritability has been shown to account for about 33-44% of the variation in sleep quality and 
length of sleep in studies of Finnish and Australian monozygotic and dizygotic twins.72,73
Sleep problems seem to increase with age and affect more women than men.5,74 A number of 
studies report an association between mental disorders such a as depression,75 anxiety,71
stress,75,76 and sleep problems. The direction of the associations is not easily determined, and 
as insomnia is included as a symptom of depression, a bidirectional association has also been 
found regarding depression and insomnia.76
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Sleep problems are also often associated with adverse general health ,71 cardiovascular 
disease, lung disorders, infectious diseases, gastrointestinal disorders including GERD, 
disorders associated with chronic pain such as fibromyalgia or back pain.75,77 An increased 
risk of sickness absence, both all cause and due to mental diagnoses, have also been seen in 
patients with at least one admission or visit to inpatient or specialist outpatient care with an 
insomnia diagnosis.78 Tobacco smoking and excessive alcohol consumption are associated 
with sleep problems,5,75 while some studies have found an association between sleep 
problems and obesity and others not.71,75
2.3.3.2 Obstructive sleep apnea 
Familial aggregation has also been seen in OSA but it has generally been believed that there 
are factors involved in the pathophysiology of OSA that are responsible for the aggregation.79
Obesity, male gender, higher age and certain cranial malformations are risk factors for 
OSA,80 81-83 and OSA has also been associated with cardiovascular disease, hypertension, 
stroke, and GERD.66 As sleep quality usually decreases in people with OSA, non-qualitative 
sleep and daytime sleepiness are also strongly linked to the disorder.  
2.3.3.3 Treatment
The standard treatment for insomnia and persistent insomnia symptoms are medication, 
cognitive behavioral therapy (CBT) and general sleep advice from a primary physician. The 
most commonly used sleep medication in Sweden is non-benzodiazepine hypnotics, such as
zolpidem and zopiclon.84
The standard management of OSA is treatment with continuous positive airway pressure 
(CPAP) during sleep, which prevents the airways from collapsing or being blocked.85 The 
standard CPAP consists of a mask that covers the nose and mouth that is connected to a small
machine that continuously blows in air. As OSA is also strongly associated with 
cardiovascular disease it has been suggested that untreated OSA may contribute to high costs
for society for these patients due to a higher demand for health care ensuing.86
2.4 SLEEP PROBLEMS AND GERD
In a number of studies, an association between sleep problems and GERD or GERS has been 
noted.6,87 These are both population-based epidemiological studies88,89 and in-hospital or open 
clinic patient studies of patients with sleep problems, and GERD patients. 90 In clinical trials,
treatment with reflux medication have been noted to also decrease sleep problems.91,92
There are several physiological gastrointestinal differences between being asleep and being 
awake, including delayed gastric emptying, decreased TLESR, decreased basal LES pressure, 
and decreased primary and secondary esophageal peristalsis during sleep.87 Indications for 
sleep problems causing or aggregating GERD include findings of sleep deprivation leading to
esophageal hyperalgesia, i.e. patients with GERD are more pain sensitive to their reflux 
symptoms when deprived of sleep.93 Sleep medication has also been proposed as a factor for 
provoking GERD by causing LES relaxations.94 Reflux events, on the other hand, are
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assumed to cause more arousals, both conscious and unconscious, compared with individuals 
without GERD,90 and arousals from sleep lead to impaired sleep quality. 
Regarding OSA and GERD, an improvement in GERD after treatment with continuous 
positive airway pressure (the standard treatment for OSA) has been noted,95 although the 
results are conflicting.96,97 It has been suggested that OSA increases nocturnal GERD by 
lowering the pressure of the lower esophageal sphincter.6 Increased GERD could in turn lead 
to increased risk of Barrett´s esophagus.
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3 AIMS
The overall aim of this thesis is to increase the knowledge of the etiology and consequences 
of GERD, and focus on the association between sleep problems and GERD. 
Specific aims 
 To provide a valid measure of changes in the prevalence with calendar time, incidence 
and spontaneous loss of GERD, in a large population-based study.
 To clarify the relation between sleep problems and GERD while adjusting for hereditary 
factors in a large population-based twin study. 
 To assess the association between sleep apnea symptoms and Barrett’s esophagus.
 To address the direction of the association between GERS and sleep problems by 
performing a large, prospective, and longitudinal cohort study.
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4 MATERIAL AND METHODS
Table 1. An overview of the design and methods of the four studies included in the thesis
Paper I Paper II Paper III Paper IV
Design Population-based 
cohort study
Population-based 
cross-sectional 
nested case-
control twin study 
Population-based 
case-control study
Population-based 
cohort study
Data source, 
country
HUNT and 
NorPD, Norway
The Swedish Twin 
Registry, Sweden
SDH and BOMS, 
Australia
HUNT, Norway
Collection years 1995-1997, 2006-
2009
1998-2002 2003-2006, 2007-
2009
1995-1997, 2006-
2009
Study exposure Age and sex Sleep problems Symptoms of 
obstructive sleep 
apnea and 
daytime 
sleepiness 
Sleep problems, 
insomnia 
symptoms and 
gastroesophageal 
reflux symptoms
Outcome Incidence, 
prevalence and 
loss of 
gastroesophageal 
reflux  
Frequent 
gastroesophageal 
reflux 
Barrett´s 
esophagus
Sleep problems, 
insomnia 
symptoms and 
gastroesophageal 
reflux symptoms
Statistical 
analysis
Proportions and 
unconditional 
logistic regression
Unconditional and 
conditional logistic 
regression
Unconditional 
logistic regression
Unconditional 
logistical 
regression
Estimate % and Odds ratio Odds ratio Odds ratio Odds ratio
Matching 
criteria
- Co-twin and reflux 
status
Age and sex  -
Confounders - Age, sex, 
education, BMI, 
and tobacco
smoking
Age, sex, BMI and 
gastroesophageal 
reflux symptoms
Age, sex, BMI, 
tobacco smoking 
and education
4.1 MATERIAL  
4.1.1 The Nord-Trøndelag Health Study 
The Nord-Trøndelag Health Study (HUNT) is a large longitudinal population-based 
collection of data, consisting of three public health surveys conducted in the county of Nord-
Trøndelag, Norway. HUNT1 data were collected in 1984-1986, HUNT2 in 1995-1997 and 
HUNT3 in 2006-2008. All residents aged 20 years or older (or if they turned 20 that year) 
were invited to answer questionnaires regarding self-reported health, quality of life and 
diseases. Participants were also invited to attend screening stations, where anthropometric 
measures such as height and weight, blood pressure and heart rate were measured.98 In 2009, 
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a condensed questionnaire called MINI-Q was sent out to non-participants in HUNT3. Data 
from HUNT2 and HUNT3 and MINI-Q were used in study I and IV. HUNT1 does not 
include questions regarding GERS and therefore could not be included. 
For HUNT2, 93,898 residents were invited and 65,237 (69%) participated. For HUNT3,
93,860 residents were invited and 50,807 (54%) participated.98 The MINI-Q was sent out to 
45,000 of the non-participants in HUNT3 and 7,591 (17%) responded.   
4.1.2 The Norwegian Prescription Database 
The Norwegian Prescription Database (NorPD) includes data on all drugs dispensed by 
prescription in Norway since the 1 January 2004. All Norwegian pharmacies are required by 
law to report all sold prescribed medications. Drugs sold over the counter without 
prescription are not covered by the database. NorPD includes information about dosage, 
package size and number of packages sold for each prescription. The database also includes 
the national identity number which is assigned to all Norwegian residents, of the recipient of 
the drug prescription. The national identity number made it possible to link the NorDP to the 
HUNT database. Information on use of the reflux medications with PPI and H2RA were used 
in study I.    
4.1.3 The Swedish Twin Register
The Swedish Twin Register was established in the late 1950s to measure the effect of tobacco 
smoking and alcohol consumption on cardiovascular disease and cancer while controlling for 
genetic liability of disease.99 The register includes more than 170,000 twins and 
approximately 85,000 complete twin pairs, and includes, in principle, all twins born in 
Sweden since 1886. Briefly, the register can be divided into three cohorts: the old cohort with 
twins born 1886-1925, the middle cohort with twins born 1926-1958, and the young cohort 
with twins born 1959 and later. Data on the old cohort were collected with postal 
questionnaires in 1961, 1963, 1967 and 1970 and included questions regarding smoking, 
alcohol consumption, diet, stress and selected diseases. The middle cohort were contacted by 
postal questionnaires in1972-1973 which included similar questions as for the older cohort,
but also included questions on personality traits and more demographic environmental 
questions including exposure to pollution.99
In 1998-2002 all twins from the old and middle cohorts were contacted again and asked to 
participate in the Screening Across the Lifespan Twin Study (SALT); a comprehensive study 
on health, disorders, diseases, family situation and socioeconomic factors. The study was 
conducted with computer assisted structured phone interviews and a total of 45,800 twins 
responded with a response rate of 65% for the old cohort and 74% for the middle cohort.100 In 
study II we used twins from SALT to study the association of sleep problems and GERD.
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4.1.4 The Study of Digestive Health and Barrett´s Oesophagus Metabolic 
Study
Study III uses data from the Barrett´s Oesophagus Metabolic Study (BOMS), which is nested 
within the study of digestive health (SDH), and cases of Barrett’s esophagus and population 
controls are defined in SDH. The SDH is a population-based case-control study that included 
newly diagnosed cases of Barrett’s esophagus aged 18-79 years in Brisbane, Australia from 
February 2003 to June 2006.101 The aim of the data collection was to identify environmental 
and genetic determinants of Barrett’s esophagus. Information about new cases was attained 
from the two major private pathology laboratories and the single public pathology laboratory. 
All patients were contacted and gave their written permission before information was 
released to the researchers. In total, 1,714 patients were diagnosed with Barrett´s esophagus 
by the laboratories. Of those, 410 (24%) did not respond, 200 (12%) declined participation 
and 1,096 (64%) agreed to be contacted by the study investigators. Of these, 487 patients 
were excluded due to a previous diagnosis of Barrett’s esophagus, and 130 patients did not 
meet the inclusion criteria, i.e. primary residence out of the study area, too ill, did not speak 
English or unwilling to give a blood sample, and were excluded. An additional criterion for 
inclusion, to ensure that the index biopsy came from the tubular esophagus, was that the 
pathology report, the pathology request form and endoscopy report relating to the index 
biopsy were reviewed by two investigators. An additional 86 patients were excluded because 
they had only intestinal metaplasia of the gastroesophageal junction. After exclusions, 393 
patients met the inclusion criteria and were included in the study. The population controls 
from the same geographical region were randomly selected from the Australian Electoral Roll 
(enrolment is compulsory by law in Australia) and matched to the cases by age (in five year 
age groups) and sex. Out of the 1,554 potentially eligible controls, 748 accepted the invitation 
(48% of all the potential controls selected from the election roll and 67% of those able to be 
contacted) and 646 of those returned a completed questionnaire. The data were collected 
through structured self-completion questionnaires and by standard telephone interviews by 
trained nurses. The data included information on height, weight, current and historical 
gastroesophageal reflux status, medication use, smoking and alcohol intake.101
Since BOMS was nested within the SDH study and the same cases and controls which were 
enrolled in the SDH study were invited to take part in this anthropometric study. The data 
were gathered between 2007 and 2009 and patients and controls were contacted via letters 
and telephone calls. Of the 359 patients from SDH who were approached, 237 (66%) 
completed the study, 69 (19%) declined to participate and 53(15%) were found to be 
ineligible. Out of the 419 age- (5-year groups) and sex-matched population controls, 247 
(59%) completed the study, 108 (26%) declined to participate and 64 (15%) were found to be 
ineligible. Participants from SDH were ineligible for BOMS if they had developed 
esophageal adenocarcinoma since SDH, died, become too ill or mentally incompetent, had 
moved out of the study area, or were uncontactable. The data were collected through self-
completed questionnaires, followed by a standardized interview by a trained research nurse 
who also used anthropometric measures. The questionnaire included questions regarding 
18
general health, tobacco smoking habits, sleep apnea symptoms, and the Epworth sleepiness 
scale. Information regarding gastroesophageal reflux symptoms, medications and previous 
endoscopies were attained during the interview. The anthropometric measures were collected 
using a standardized protocol and consisted of height, weight, waist circumference, hip 
circumference, neck circumference and sagittal abdominal diameter.59
4.2 MEASURES
4.2.1 Assessment of gastroesophageal reflux 
According to the Montreal definition, a GERD diagnosis can be given without endoscopy or 
pH measurement.9 In all four studies GERS/GERD was self-assessed, i.e. the participants 
answered a questionnaire or participated in an interview either face-to-face or by telephone. 
In studies I and IV (HUNT study), GERS was assessed with the question “To what degree 
have you had heartburn or acid regurgitation during the previous 12 months?”  The response 
alternatives were “no complaints”, “minor complaints” or “severe complaints”. Participants
answering “minor complaints” or “severe complaints” were categorized as having any GERS,
and those who reported “severe complaints” were categorized as having severe GERS. The 
same reflux question was used in HUNT2, HUNT3 and Mini-Q and has been validated in a 
previous study from our group.34   
In study I the question “If you have had heartburn or acid regurgitation during the previous 
12 months, how often do you have complaints?”, which was asked only in Mini-Q, was also 
used. The response alternatives for this question were “daily”, “weekly” or “less frequent”. If 
a participant had answered “daily” or “weekly” it was categorized as having “at least weekly 
GERS”. This question had also been used in the previously mentioned validation study of 
HUNT2 data. That validation study found that 95% of participants reporting severe GERS at 
HUNT2 reported more than weekly symptoms or reported daily anti-reflux medication use,
and 25% of those who reported minor symptoms in HUNT2 also reported more than weekly 
symptoms or daily medication use.34 These numbers were used as weights to estimate more 
than weekly symptoms in HUNT2 and the corresponding numbers from Mini-Q were used as 
weights to estimate more than weekly symptoms in HUNT3.          
In study II we used a battery of 10 validated questions to assess GERD. The participants were 
asked they had heartburn, pain behind the breastbone, or regurgitation of bitter fluid or acidic
fluids into the mouth. If a positive response was given to any of these questions, seven 
additional questions were asked regarding duration and frequency of symptoms, radiation of 
pain towards the neck, antacid relief, and use of histamine-receptor antagonists or proton 
pump inhibitors. GERD was defined by at least weekly occurrence of pain behind the breast 
bone, regurgitation of bitter or acidic fluids, or heartburn. Participants who reported having 
pain behind the breast bone 1-3 times a month in combination with i) waking up at night due 
19
to the pain, ii) use of medications to prevent the pain, iii) pain radiating towards the neck, or 
iv) antacids not reducing the pain, were also classified as having GERD.
In study III GERD was used as a potential confounding factor and the participants were asked 
“Have you ever had acid reflux (not including acid reflux during pregnancy)?” If the 
participant answered “yes” he/she was asked “Thinking about the time when your acid reflux 
happened most frequently, how often did you have it?” Symptoms were then categorized as 
“at least weekly symptoms” or “less than weekly symptoms”. People with no GERS were 
categorized into the group “less than weekly symptoms”. 
4.2.2 Assessment of Barrett´s esophagus
Barrett’s esophagus was assessed only in study III by analyzing the presence of intestinal 
metaplasia (columnar epithelium with goblet cells) in biopsies taken from the esophagus by 
upper gastrointestinal endoscopy. An additional criterion for receiving the Barrett´s diagnosis 
and to ensure that the index biopsy came from the tubular esophagus, was that the pathology 
report, the pathology request form and endoscopy report relating to the index biopsy was 
reviewed by two investigators. 
4.2.3 Assessment of sleep problems, insomnia symptoms and symptoms of 
obstructive sleep apnea
Sleep problems were assessed in studies II and IV, insomnia symptoms in study IV and 
symptoms of obstructive sleep apnea in study III.
In study II, sleep problems were assessed with three questions from the Karolinska sleep 
questionnaire.102,103 Participants were asked how often during the last six months they had 
experienced feeling “not rested when waking up”, “disturbed sleep” and “waking up too early 
and not able to go back to sleep”. Each item had 5 response alternatives and the responses 
“never” and “seldom” were categorized as “seldom”, “sometimes” was kept and “mostly”
and “always” grouped together as “often”. An insomnia index was also constructed based on 
the responses of the 3 items, and 0 points were given for “seldom”, 1 point for “sometimes”
and 2 points for “often”. The scores were summed and a score of 4-6 points or a response of 
“often” was classified as “often having sleep problems”, 1-3 points as “sometimes having 
sleep problems” and 0 points as “seldom having sleep problems”.     
In study III, symptoms of OSA were measured by daytime sleepiness and with a sleep apnea 
symptom index. The Epworth Sleepiness Scale (ESS), which consists of 8 items which 
measures the participants’ likelihood to “doze off” in different everyday situations, was used 
to measure daytime sleepiness. Each item had 4 response alternatives: “would never doze”, 
“slight chance of dozing”, “moderate chance of dozing”, and “high chance of dozing”. Scores 
for each item were given; 0 for never, up to 3 for “high chance of dozing” and when added 
together a score of 10 or higher was defined as having excessive daytime sleepiness. The 
scale has been constructed as a proxy for OSA with which it has been shown to correlate 
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well.104 Symptoms of sleep apnea were assessed with a sleep apnea symptom index, which 
consists of 3 questions. Participants were asked how often during the last month they had (or 
had been told they have) the sleep related symptoms: “snorting or gasping”, “load snoring”
and “breathing stops, choking or struggle for breath”.  For each item the participant could 
answer “never”, “rarely, “less than once a week”, “1-2 times a week”, “3-4 times a week”, 
“5-7 times a week” or “don´t know” and the answers were coded as 0-4, with the answer 
“don´t know” set to missing. The items where then summarized and the mean values 
calculated. A mean score of <1 was defined as “never” having sleep apnea symptoms, 1-<2 
as “rarely” having sleep apnea symptoms and 2 or higher as “often” having sleep apnea 
symptoms. 
In study IV, sleep problems were assessed with the question “Have you had difficulty falling 
asleep during the last month?” in HUNT2, with response alternatives “almost every night”, 
“often”, “now and again”, or “never”. The answers “almost every night” or “often” were 
classified as having sleep problems. In HUNT3/Mini-Q sleep problems were assessed with a 
similar question: “How often during the last 3 months have you had difficulty falling asleep 
at night?”, with response alternatives “never/seldom”, “sometimes”, or “several times a 
week”. Participants who answered “several times a week” were classified as having sleep 
problems. Insomnia symptoms were assessed with 3 questions in HUNT2: “Have you had 
difficulty falling asleep during the last month?”, “During the last month, have you woken too 
early and not been able to go get back to sleep?” and “During the last year, have you been 
troubled by insomnia to such a degree that it affected your work?”. A participant was defined 
as suffering from insomnia symptoms if responding “almost every night” or “often” to 
initiating or maintaining sleep, in combination with experiencing impaired work performance 
due to insomnia during the last year. In HUNT3, insomnia symptoms were assessed by the 
questions: “How often during the last 3 months have you had difficulty falling asleep at 
night?”, “How often during the last 3 months have you woken up too early and couldn´t go 
back to sleep?”, and “How often during the last 3 months have you felt sleepy during the 
day?”. If a participant answered “several times a week” on initiating or maintaining sleep, 
and “feeling sleepy during the day” that participant was considered as suffering from 
insomnia symptoms. Since there was no question to assess any influence of sleep disturbance 
on daily life in Mini-Q, the assessment of insomnia symptoms was restricted to HUNT2 and 
HUNT3.
4.2.4 Assessment of zygosity 
To assess zygosity in the twin pairs in study II, each twin independently answered the 
question: “During childhood, were you and your twin partner as alike as ‘two peas in a pod’
or ‘not more alike than siblings in general?’ If both twins in the pair answered that they were 
“alike as two peas in a pod” they were classified as monozygotic (MZ), and if both answered 
that they “were not more alike than siblings” they were classified as dizygotic (DZ). If the 
twins answered differently they were categorized as “not determined”. This method of 
determining zygosity has been shown to be 98% accurate compared to DNA-testing.99
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4.2.5 Assessment of additional potential confounders
All studies controlled for potential confounding by age and sex. In studies II, III and IV we 
also assessed obesity, tobacco smoking and education in the main analyses while we used
obesity and GERS in study III. Obesity was measured by body mass index (BMI), the weight 
in kilograms divided by the square of the height (kg/m2). BMI was analyzed in categories;
BMI <25 was classified as normal weight, BMI 25-29.9 as overweight and BMI ≥30.0 as 
obese, all according to the WHO classification. WHO does further distinguish between 
underweight (BMI<18.5) and normal weight (BMI 18.5-24.9) but these categories were 
collapsed and labelled “normal weight” in these studies. Height and weight were measures by 
trained personnel in study III and study IV (HUNT2 and HUNT3) and self–reported in study 
II and study IV (Mini-Q). Tobacco smoking was self-assessed and smoking habits 
categorized as “current smoker”, “previous smoker”, or “never smoker”, in all three studies. 
Education was used as a proxy for socio-economic status in all three studies, and number of 
years of education grouped in three categories (0-9, 9-12, >12) in study II and two in study IV
(≤12, < 12). In study III, highest type of education was used instead (divided into high school, 
tech/trade collage, or university). In study III we also assessed neck circumference which was 
measured by a trained research nurse. Neck circumference was divided into tertiles [t] with
sex specific thresholds from the population controls (males t1: 0-39.05, t2 39.05-41.40, or t3:
>41.40; females t1: 0-33.45, t2: 33.45-35.55, or t3: >35.55).
4.3 METHODS   
4.3.1 Study I
4.3.1.1 Design
A population-based cohort study including residents of at least 20 years of age in the county 
of Nord-Trøndelag, who reported GERS status in the health surveys HUNT2 (1995-1997)
and HUNT3/Mini-Q (2006-2009). 
4.3.1.2 Statistical analysis
Prevalence of GERS was calculated as the proportion of persons in HUNT2 and 
HUNT3/Mini-Q who reported any (minor or severe) GERS or severe GERS, respectively. 
Prevalence of at least weekly GERS was calculated by multiplying the proportions from the 
validation study in HUNT234 with severe and minor GERS in HUNT2, and by proportions 
from Mini-Q in HUNT3. 
The cumulative incidence of GERS was calculated from participants who reported no GERS 
in HUNT2 and then reported any or severe GERS in HUNT3/Mini-Q. The spontaneous 
cumulative loss of GERS was calculated from participants who reported any or severe GERS 
in HUNT2 and later reported no GERS at HUNT3/Mini-Q. In order to measure only 
spontaneous loss of GERS, participants using prescribed reflux medications at least weekly 
were excluded. Information on medication usage was obtained from the NorPD and matched 
to the participants by their national identity number. Average annual cumulative incidence 
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(average annual percentage change) were calculated by the formula (exp (cumulative 
proportion)-1)/11 years. The same formulae were used to calculate annual cumulative 
spontaneous loss of GERS. We also stratified the incidence, prevalence and spontaneous loss 
of GERS by age (<40, 40-49, 50-59, 60-69, and ≥70 years) and sex, and calculated 95% 
confidence intervals.
To measure differences in incidence and spontaneous loss of GERS between age groups in 
men and women, we calculated odds ratios (OR) with logistic regression. An interaction term 
was included in the model to measure the joint age and sex effect. The statistical analyses 
where performed with the software Stata/IC 11.1 for Windows by StataCorp LP.
4.3.2 Study II
4.3.2.1 Design
A population-based cross-sectional nested case-control twin design including twins 65 years 
of age or older who had answered GERD and sleep problem items in the Screening across the 
lifespan in study, in the Swedish Twin Registry.   
4.3.2.2 Statistical analysis
The co-twin control method was used to adjust for genetic and early environmental factors 
between sleep problems and GERD and the analyses were performed in three steps. First, the 
association between sleep problems and GERD was analyzed with unconditional logistic 
regression using the whole cohort in the analyses. Because of the within-pair dependency, the 
cohort included both pairs and single twins, so generalized estimated estimations (GEE) 
models were used in order to avoid underestimation of the variance. In the second step, 
within-pair co-twin analyses with dizygotic (DZ) twins only were performed with conditional 
logistic regression. Only complete twin pairs discordant for GERD (one twin had GERD the 
other not), were included in this analysis. In the third step, within-pair co-twin analyses with 
monozygotic (MZ) twins discordant for GERD were analyzed with conditional logistic 
regression. In all analyses crude models and models which adjusted for education level, BMI 
and tobacco smoking were calculated. In the models including the whole cohort we also 
adjusted for age and sex. By including twin pairs discordant for the outcome, and comparing
estimates from full-cohort analyses with estimates discordant DZ twins and MZ twins, it is 
possible to adjust for genetic and early environmental factors. This is due to the fact that MZ 
twins share 100% of their genes and DZ twins on average 50% of their genes. If an 
association is found in the external analysis, the analysis with the whole cohort, and the 
association disappears for the within-pair analyses for both DZ and MZ twins, there is an 
indication of confounding by early environmental factors. This is because twins usually share 
the environment in the uterus and are also usually brought up together and this factor does not 
vary between DZ and MZ twins. If the association instead is seen in the within-pair analysis 
for DZ twins but disappears for MZ twins there this indicates genetic confounding. Intraclass 
correlations (correlations within GERD and sleep problems separately) and twin cross-trait 
correlations (correlations between GERD and sleep problem items) were estimated to further 
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study the influence of genes. Polychoric correlations were used for these analyses. In a sub-
analysis of participants reporting pain behind the breastbone or heartburn, we analyzed if 
participants reported nocturnal symptoms suffered more often from sleep problems, using 
Pearson’s chi squared test. SAS software 9.2 (SAS Institute, Cary, NC) was used for all 
analyses.                    
4.3.3 Study III
4.3.3.1 Design 
A population-based case-control study, including histologically confirmed cases of Barrett´s 
esophagus and matched population controls from Brisbane, Australia.     
4.3.3.2 Statistical analysis
In this study, baseline characteristics of Barrett´s esophagus and population controls were 
first compared. These characteristics included sex, age, BMI, tobacco smoking, education, 
GERS and neck circumference. Pearson’s chi-square test was used to evaluate potential 
differences between cases and controls. In a second step we studied the same baseline 
characteristics among population controls only, and compared participants with and without 
excessive daytime sleepiness, and participants with different frequencies of sleep apnea 
symptoms. Finally, we used unconditional logistic regression and estimated OR and 95% 
confidence intervals (95% CI) for associations between excessive daytime sleepiness, sleep 
apnea symptoms and Barrett’s esophagus. The main exposures excessive daytime sleepiness 
and sleep apnea symptoms were analyzed separately in three models: 1) adjusted for age and 
sex only 2) adjusted for age, sex and BMI, and 3) adjusted for age, sex, BMI and GERS. 
Tobacco smoking and education seemed to be associated with Barrett´s esophagus (from the 
descriptive analyses) but not with excessive daytime sleepiness and were therefore not 
included in the adjusted models. Statistical analyses were performed with software SAS 
version 9.2 (SAS institute, Cary, NC).
4.3.4 Study IV
4.3.4.1 Design 
A longitudinal population-based cohort study (the HUNT study) conducted in Nord-
Trøndelag county, Norway, including HUNT2 (1995-1997) and HUNT3/Mini-Q (2006-
2009).
4.3.4.2 Statistical analysis
In the analyses we assessed two levels of GERS, any GERS and severe GERS, and two levels
of sleep problems, general sleep problems and insomnia symptoms. As the questions used to 
assess insomnia symptoms were not included in Mini-Q, analyses of insomnia symptoms
either as outcome or exposure, were restricted to HUNT2 and HUNT3. Thus, the analyses 
were conducted in 4 cohorts (see flowchart below). 
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Figure 1. Flowchart over the participants in HUNT2, HUNT3 and Mini-Q and the four study 
sub-cohorts. Cohort 1 measured the cumulative incidence of any and severe gastroesophageal 
reflux symptoms (GERS) in HUNT3/Mini-Q among participants without GERS in HUNT2 
with sleep problems as exposure. Cohort 2 measured the cumulative incidence of any and 
severe GERS in HUNT3 among participants without GERS in HUNT2 and with insomnia 
symptoms as exposure. Cohort 3 measured the cumulative incidence of sleep problems in 
HUNT3/Mini-Q among participants without sleep problems in HUNT2 with were any and 
severe GERS as exposures. Cohort 4 measured the cumulative incidence of insomnia
symptoms in HUNT3 among participants without insomnia symptoms in HUNT2 with any
and severe GERS as exposures.
The four sub-cohorts were analyzed separately. Analyzes were performed with unconditional 
logistic regression and OR and 95% CI were calculated. The main exposures (sleep problems, 
insomnia symptoms, any GERS and severe GERS) were all categorized in the same way: 1) 
no exposure, 2) exposure in HUNT2, but not in HUNT3/Mini-Q, 3) exposure in 
HUNT3/Mini-Q, but not in HUNT2, and 4) exposure in both HUNT2 and HUNT3/Mini-Q.
In this way we wished to see if prolonged exposure to GERS or sleep problem/insomnia 
symptoms would lead to increased GERS or sleep problems/insomnia symptoms.
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In the multivariable analyses we adjusted for sex, age (< 40, 40-49, 50-59, 60-69, or ≥70 
years), BMI (categorized according to WHO classification <25 normal or low weight, 25-30 
overweight, or ≥30 obesity), cigarette smoking status (current smoker, previous smoker, or 
never smoker), and educational level (≤12 years or >12 years). SAS software 9.2 (SAS 
Institute, Cary, NC) was used for all analyses.
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5 RESULTS
5.1 STUDY I
5.1.1 Population and Characteristics 
GERS status was reported by 58,869 (64% of the eligible) in HUNT2 and by 44,997 (49%) in 
HUNT3/MINI-Q. Between HUNT2 and HUNT3/MINI-Q, 10,535 participants either died or 
moved out of the county and 18,724 choose not to participate, leaving 29,610 who reported 
GERS-status and answered both HUNT2 and HUNT3/MINI-Q (see the flowchart on the page 
below). 
Figure 2. Flowchart of patients reporting gastroesophageal reflux symptoms (GERS) in 
HUNT2 and HUNT3/Mini-Q with the number of individuals (N) at each stage and response 
rates. Response rates were calculated from those eligible, excluding those who had died or 
were no longer resident in the county (non-eligible). Published in GUT (2012)
Oct;61(10):1390-7  
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5.1.2 Prevalence 
Between the surveys in 1995-1997 and 2006-2009, the prevalence of any GERS increased by 
30%, from 31.4% to 40.9% and the prevalence of severe GERS increased by 24%, from 5.4% 
to 6.7%. The estimated prevalence of weekly GERS increased by 47%, from 11.6% to 17.1%
(Table 2).
The prevalence of GERS increased for both sexes and all age groups, but for severe GERS 
the prevalence increased mainly among those in the middle age group (data not shown). The 
estimated prevalence of at least weekly GERS also increased for all age groups and the 
largest relative change were seen middle-aged women men above 70 years of age (Figure 3).
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Table 2 An overview of the prevalence of any, severe and at least weekly gastroesophageal 
reflux symptoms (GERS). 1 A complete table can be seen in study I.
HUNT 2 HUNT3/ Mini-Q
1996-1997 2006-2009 Relative 
n = 58869 n = 44997 change2
Prevalence any GERS1 n GERS % n GERS % %
Total 18460 31.4 18389 40.9 30.3
Women 9104 29.7 9526 38.8 30.5
Men 9356 33.1 8860 43.3 30.9
Prevalence severe GERS
Total 3167 5.4 2994 6.7 23.7
Women 1603 5.2 1629 6.6 26.7
Men 1564 5.5 1364 6.7 20.6
Prevalence weekly GERS
Total 6835 11.6 7692 17.1 47.2
Women 3400 11.1 4036 16.4 48.0
Men 3435 12.2 3654 17.9 47.1
1Any GERS : minor plus severe complaints with heartburn and acid regurgitation.  Severe GERS: severe 
complaints only. Weekly GERS: at least weekly complaints of heartburn and acid regurgitation.
2 Relative prevalence change: (prevalence HUNT3/Mini-Q  -  prevalence HUNT2)/ prevalence HUNT2.
Figure 3 Prevalence of estimated at least weekly GORS for each sex and age groups in 1995-
1997 (HUNT2) and 2006-2009 (HUNT3/Mini-Q with 95% CI (vertical lines)
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5.1.3 Incidence 
During the average 11 years of follow-up from 1995-1997 to 2006-2009, the cumulative 
incidence of any GERS was 29.1%, which corresponded to an average annual incidence of 
3.07%. The cumulative incidence of severe GERS was 2.5% and slightly higher among 
women (2.8%) than in men (2.1%) (Table 3). The corresponding annual incidence of severe 
GERS was 0.23%.
Table 3 Overview of the cumulative incidence and spontaneous loss of gastroesophageal 
reflux symptoms (GERS).1 Complete tables can be seen in the appendix in study I.
Cumulative incidence of any GERS Cumulative spontaneous loss of any
GERS
Incidence any 
GERS Number
%
Number %
Total 5904 29.1 Total 2112 22.7
Women 3209 28.2 Women 1118 23.9
Men 2695 30.2 Men 994 21.5
Cumulative incidence of severe GERS Cumulative spontaneous loss of severe
GERS
Total 510 2.5 Total 195 12.6
Women 319 2.8 Women 93 11.7
Men 191 2.1 Men 102 13.5
1The cumulative incidence was calculated from those with no GERS at HUNT2 (n=2033) and spontaneous loss 
of any GERS from those with any GERS at HUNT2 (n= 9,299) and spontaneous loss of severe GERS from 
those with severe GERS at HUNT2 (n= 1,553). Participants using anti-reflux medication at least weekly were 
excluded.    
Women at the age 60-69 had the highest incidence of any GERS (33.3%), while the lowest 
incidence of any GERS was seen in women below the age of 40 (20.5%). In men the 
cumulative incidences of any GERS were similar over all age categories (29.3%- 31.3%).
The cumulative incidence of severe GERS were similar between age groups but slightly in 
women 50-69 years of age (Figure 4).
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Figure 4. Cumulative incidence of any and severe GERS for each sex and age group (age at 
follow-up) between 1995-1997 and 2006-2009 (HUNT3/Mini-Q) with 95% CI (vertical 
lines).
5.1.4 Spontaneous loss of GERS
The cumulative loss of any GERS during the study period was 22.7%, when excluding the 
286 participants (12%) using antireflux medication at least weekly. This corresponded to an 
average annual spontaneous loss of 2.32%. The cumulative loss of severe GERS was 12.6% 
when excluding the 89 participants (31%) using antireflux medication at least weekly (Table 
3). This corresponded to an average annual spontaneous loss of 1.22%.The spontaneous loss 
decreased with increasing age for both sexes, but this was particularly evident among women
(Figure 5).
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Figure 5 Cumulative spontaneous loss of any and severe GORS for each sex and age groups 
(age at –follow-up) between 1995-1997 (HUNT2) and 2006-2009 (HUNT3/Mini-Q with 
95% CI (vertical lines). 
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5.2 STUDY II 
5.2.1 Study participants
Of the 8,951 twins that were eligible for inclusion in this study, we excluded 937 (10%) due 
to missing information about GERD. Of the twins included in the descriptive analysis, 1,327 
(17%) had GERD. Participants with GERD were to a greater extent overweight (42%) and 
obese (9%) than participants without GERD, where 35% were overweight and 7% obese. 
Previous tobacco smoking was more common among participants with GERD, 36% 
compared to 31%, while current smoking was as common in both groups, 11% compared to 
10%. Of the 7,857 twins included in the final external analyses (157 twins were excluded due 
to missing information about insomnia), 4,682 twins had a co-twin in the sample (2,341 
pairs). Of these, 356 DZ pairs and 210 MZ pairs were discordant for GERD and were used in 
the within-pair analyses. The age and sex distributions were similar for DZ and MZ twins 
(Table 4). 
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Table 4 The distribution of gastroesophageal reflux disease (GERD) in same-sexed dizygotic 
(DZ) and monozygotic (MZ) twin pairs. 
DZ pairs
n (%)
MZ pairs
n (%)
Concordant, both twins have GERD 51 (4) 52 (6)
Concordant, neither twin has GERD 1004 (71) 647 (71)
Discordant, one twin has GERD, and not the other 356 (25) 210 (23)
Sex, same-sexed discordant pairs 
Men 137 (38) 80 (38)
Women 231 (61) 130 (62)
Age (in years), discordant pairs
64-74 259 (73) 149 (71)
≥75 97 (27) 61 (29)
5.2.2 The association between sleep problems and GERD
In the external analyses a dose-dependent association was seen among twins with increasing 
sleep problems, in all of the sleep problem exposures, and occurrence of GERD (Table 5). 
Participants who often experienced sleep problems (according to the insomnia index) had a 2-
fold increased occurrence of GERD compared with those who seldom experienced sleep 
problems (OR 2.0; 95% CI 1.8-2.4). Similarly, those who sometimes experienced sleep 
problems had a 50% increased occurrence compared with those who seldom experienced 
sleep problems (OR 1.5; 95% CI 1.3-1.7). In the co-twin control analyses with DZ twins, the 
associations of often having sleep problems compared to seldom having sleep problems 
remained, while the associations decreased and become non-significant in co-twin analysis 
with MZ twins. This could be an indication of genetic confounding, but the twin cross-trait 
correlations between the insomnia index and GERD were low, 0.077 in DZ twin-pairs and 
0.043 in MZ twin pairs. If there is a genetic effect, the correlation in MZ pairs should be 
higher than for DZ pairs and therefore there does not seem to be strong confounding by 
heredity present. The separate items “not rested when waking up”, “disturbed sleep” and 
“waking up too early” showed a similar pattern between the external, DZ and MZ analyses as 
the sleep insomnia index, except for “disturbed sleep” where “sometimes” having disturbed  
sleep  showed higher risk for GERD than “often” among DZ twins (OR 1.9; 95% CI 1.2-1.9  
and OR 1.7; 95% CI 1.0 -2.8), and the effect of sometimes having disturbed sleep remained 
among MZ twins (Table 5). Finally, in a sub-analyses of those reported waking up at night 
due to pain behind the breastbone or heartburn, 16% “often” had disturbed sleep compared to 
11% among those who did not and there was a significant association between nocturnal 
reflux symptoms and disturbed sleep (χ2 8.6; p-value 0.01). 
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Table 5 Associations between sleep problems and gastroesophageal reflux disease (GERD)
External analysis Co-twin analysis DZ 
twins
Co-twin analysis MZ 
twins
n = 7,857 n = 365 pairs n= 210 pairs
Exposure GERDa adjusteda adjustedb adjustedb
Insomnia indexd n (%) OR 95% CI OR 95% CI OR 95% CI
Seldom 456 (35) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Sometimes 438 (34) 1.5 1.3-1.7 1.5 1.0-2.2 1.3 0.8-2.2
Often 403 (31) 2.0 1.8-2.4 2.2 1.5-3.4 1.5 0.9-2.7
Not rested when 
waking up
Seldom 842 (65) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Sometimes 261 (20) 1.5 1.3-1.8 1.5 1.0-2.3 1.6 0.9-2.8
Often 197 (15) 1.7 1.5-2.1 2.1 1.3-3.3 1.9 0.9-3.9
Disturbed sleep
Seldom 872(67) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Sometimes 269 (21) 1.7 1.4-1.9 1.9 1.2-2.9 1.9 1.0-3.6
Often 162 (12) 2.0 1.6-2.4 1.7 1.0-2.8 1.4 0.7-3.1
Waking up too 
early
Seldom 709 (54) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Sometimes 357 (27) 1.3 1.1-1.5 1.1 0.7-1.6 1.5 0.9-2.4
Often 240 (18) 1.9 1.6-2.3 1.7 1.1-2.7 1.5 0.8-2.9
OR, odds ratio; CI, confidence interval; MZ, monozygotic; DZ, dizygotic; 
aThe different numbers of GERD cases for the four sleep exposures are due to different numbers of missing 
observations in the sleep questions.
bORs adjusted for age, sex, educational level, body mass index, and tobacco smoking.
cORs adjusted for educational level, body mass index, and tobacco smoking. Genetic and early environmental 
factors, sex and age are adjusted for by the within-pair structure.  
5.3 STUDY III
Included in this study were 237 cases of Barrett’s esophagus and 247 controls. The
characteristics differed regarding obesity (BMI >30) (35% among cases, 23% among 
controls) neck circumference (44% of cases were in the highest tertile compared with the 
expected 33% among controls) and smoking habits (14% current and 53% previous smokers 
among cases versus 9% current smokers and 34% previous smokers among controls). The 
cases also tended to have lower education (43% had high school as highest education 
compared with 35% among controls) and a higher proportion of frequent GERS (85% among 
cases compared with 38% among controls). Of the 247 controls, all answered the Epworth 
sleepiness scale, while 214 controls reported information about sleep apnea status (the 33 
participants who answered “do not know” were set to missing) (Table 6). The distributions of
smoking status and education level were similar for those with and without excessive daytime 
sleepiness. Compared with controls without daytime sleepiness, a higher percentage of 
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controls with daytime sleepiness had a BMI ≥30 (32% vs. 21%) but otherwise the distribution 
of BMI was fairly similar between groups. At least weekly GERS was more common among 
participants with daytime sleepiness (57% vs. 34%). In a multivariable model including at 
least weekly GERS, BMI, tobacco smoking and education, a more than 2-fold increased 
occurrence of excessive daytime sleepiness was seen among participants with at least weekly 
GERS compared to participants with less than at least weekly GERS (OR 2.60; 95% CI 1.28-
5.30).
The distribution of smoking and education were similar regardless of frequency of sleep 
apnea symptoms, while a higher percentage of controls with frequent sleep apnea symptoms 
had a BMI ≥30 (50%), compared with those who never had sleep apnea symptoms (14%). 
Large neck circumference was more common among those who “often” had sleep apnea 
symptoms (64%) compared with those who “never” had (22%) (Table 6). In a multivariable 
model  controls with at least weekly GERS had a 3-fold increased occurrence of high level of 
sleep apnea symptoms compared to those with less than weekly GERS (OR 3.08; 95% CI 
1.69-5.62), after adjusting for BMI, tobacco smoking and education.
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Table 6 Characteristics for excessive daytime sleepiness and sleep apnea symptoms among 
population controls.
Excessive daytime 
sleepiness
Sleep apnea symptoms
n = 247 n = 2141
present absent never rarely often
n (%) n (%) p-value n (%) n (%) n (%) p-value2
Body mass index
< 25 kg/m2 8 (18) 60 (30) 42 (34) 13 (21) 3 (11)
25-29.99 kg/m2 22 (50) 100 (49) 65 (52) 31 (51) 11 (39)
≥ 30 kg/m2 14 (32) 43 (21) 0.1759 18 (14) 17 (28) 14 (50) 0.0005
Neck circumference3
Tertile 1 11 (25) 74 (36) 54 (43) 16 (26) 3 (11)
Tertile 2 15 (34) 66 (33) 44 (35) 19 (31) 7 (25)
Tertile 3 18 (41) 63 (31) 0.2892 27 (22) 26 (43) 18 (64) <.0001
Tobacco smoking
Never smoker 24 (55) 118 (58) 76 (61) 37 (61) 13 (46)
Ex-smoker 16 (36) 68 (34) 39 (31) 19 (31) 11 (39)
Current smoker 4 (9) 17 (8) 0.9094 10 (8) 5 (8) 4 (14) 0.6615
Education
High school or lower  18 (41 66 (33) 38 (31) 25 (42) 9 (35)
Tech/trade College 16 (36) 80 (40) 49 (40) 19 (32) 13 (50)
University studies 10 (23) 53 (27) 0.6153 37 (30) 16 (27) 4 (15) 0.3144
Gastroesophageal 
reflux symptoms4
< weekly 19 (43) 133 (66) 94 (75) 35 (57) 7 (25)
≥ weekly 25 (57) 68 (34) 0.0044 31 (25) 26 (43) 21 (75) <.0001
133 patients were missing information about sleep apnea symptoms as the answer “do not know” is coded as 
“missing”.
2Pearson’s chi-square test 
3The cut-offs for neck circumference were tertiles (t): males t1 0-39.05; t2 39.05-41.40, t3 > 41.40, females t1 0-
33.45; t2 33.45-35.55; t3 > 35.55
4The participants were asked how often they had acid regurgitation or heartburn when the symptoms were most 
frequent.
In the analyses of excessive daytime sleepiness and occurrence of Barrett’s esophagus, a 40% 
increased occurrence was indicated in the minimally adjusted model, but the association did 
not reach statistical significance (OR 1.42; 95% CI 0.91-2.21) (Table 7). After adjustment for 
BMI and GERS the increased point estimate disappeared. A similar pattern was seen for 
sleep apnea symptoms. An initial non-statistical significant association of 58% among those 
often having sleep apnea symptoms and occurrence for Barrett’s esophagus were noted in the 
first model (OR 1.58; 95% CI 0.91-2.76), but disappeared after adjusting for BMI and GERS. 
No association was seen among those who rarely experienced sleep apnea symptoms and 
Barrett´s esophagus.    
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Table 7 Excessive daytime sleepiness, sleep apnea symptoms and the risk of Barrett’s 
esophagus measured with odds ratio (OR) and 95% confidence interval (CI).
Barrett's 
esophagus 
cases
Controls Minimally 
adjusted model1
Partially 
adjusted 
model2
Fully adjusted 
model3
n (%) n (%) OR (95% CI) OR (95% CI) OR (95% CI)
Excessive 
daytime 
sleepiness4
Absent 181 (76) 203 (82) 1 (reference) 1 (reference) 1 (reference)
present 56 (24) 44 (18) 1.42 (0.91-2.21) 1.34(0.85-2.10) 0.99(0.60-1.65)
Sleep apnea 
symptoms5
Never 107 (55) 125 (58) 1 (reference) 1 (reference) 1 (reference)
Rarely 50 (26) 61 (29) 0.94 (0.60-1.49) 0.86 (0.54-1.37) 0.76 (0.44-1.31)
Often 39 (20) 28 (13) 1.58 (0.91 -2.76) 1.33 (0.75-2.35) 0.74 (0.39-1.40)
1Adjusted for age and sex
2Adjusted for age, sex and body mass index 
3Adjusted for age, sex, body mass index and gastroesophageal reflux symptoms
4Measured with the Epworth sleepiness scale
5Measured with the sleep apnea index 
5.4 STUDY IV
5.4.1 Characteristics 
The characteristics of the 4 sub-cohorts of study IV are presented in Table 8. The mean age of 
the participants (measured at HUNT2) was similar in all cohorts, but only slightly lower in 
cohort 1, with mean 43 years compared to 44 in the other cohorts. More women than men 
were represented in all cohorts and a higher percentage of participants in cohort 3 and 4 were 
obese (20% compared to 17% in cohort 1 and 2). 
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Table 8 Characteristics of the 4 cohorts. Cohort 1 measured the cumulative incidence of any 
and severe gastroesophageal reflux symptoms (GERS) in HUNT3/Mini-Q among 
participants without GERS in HUNT2 with sleep problems as exposure. Cohort 2 measured 
the cumulative incidence of any and severe GERS in HUNT3 among participants without 
GERS in HUNT2 and with insomnia symptoms as exposure. Cohort 3 measured the 
cumulative incidence of sleep problems in HUNT3/Mini-Q among participants without sleep
problems in HUNT2 with were any and severe GERS as exposures. Cohort 4 measured the 
cumulative incidence of insomnia symptoms in HUNT3 among participants without insomnia 
symptoms in HUNT2 with any and severe GERS as exposures.
Cohort 1 Cohort 2 Cohort 3 Cohort 4
Cumulative 
incidence of 
any and 
severe
GERS. 
Exposure 
sleep 
problems
Cumulative 
incidence of 
any and 
severe
GERS. 
Exposure 
insomnia 
symptoms
Cumulative 
incidence of 
sleep 
problems.
Exposure any
and severe
GERS
Cumulative 
incidence of 
insomnia 
symptoms. 
Exposure any 
and severe
GERS
All, N (%) 16,754 (100) 14,946 (100) 21,500 (100) 18,025 (100)
Women, N (%) 9,602 (57) 8,649 (58) 11,736 (55) 9,872 (55)
Men, N (%) 7,152 (43) 6,297 (42) 9,764 (45) 8,153 (45)
Age in years1
Mean (SD) 43 (12) 44 (11) 44 (11) 44 (11) 
Median (range) 44 (19-67) 44 (19-67) 44 (19-67) 44 (19-67)
Body mass index
<25, N (%) 4,812 (29) 4,270 (29) 5,469 (26) 4,533 (25)
25-30, N (%) 9,036 (54) 8,110 (54) 11,711 (55) 9,927 (55)
≥30, N (%) 2,794 (17) 2,536 (17) 4,187 (20) 3,536 (20)
Cigarette smoking
Current, N (%) 2,486 (15) 2,151 (15) 3,309 (16) 2,644 (15)
Previous, N (%) 6,474 (40) 5,763 (40) 8,556 (41) 7,124 (41)
Never, N (%) 7,294 (45) 6,556 (45) 9,002 (43) 7,681 (44)
Education4
≤12 years, N (%) 11,930 (72) 10,624 (72) 15,716 (74) 13,175 (74)
>12 years, N (%) 4,661 (28) 4,186 (28) 5,573 (26) 4,680 (26)
1Age was measured in HUNT2.
5.4.2 Sleep problems and insomnia symptoms as risk factors for developing 
any and severe GERS
In total, 4,850 participants (29%) developed any GERS and 396 (2%) developed severe 
GERS between HUNT2 and HUNT3/Mini-Q. 
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Any GERS was more common among those with sleep problems in both HUNT2 and 
HUNT3/Mini-Q compared to those without sleep problems (adjusted OR 1.84; 95% CI 1.48-
2.30) and this was true also for those with sleep problems in HUNT2 only (1.51; 95% CI 
1.23-1.84) (Table 9). The same pattern was seen for the incidence of severe GERS among 
those with sleep problems at both HUNT2 and HUNT3/Mini-Q compared to those without 
sleep problems (OR 3.53; 95% CI 2.28-5.48) and for those with sleep problems in HUNT2 
only compared to non-exposed (OR 2.06; 95% CI 1.26-3.36).
When the exposure was restricted to insomnia symptoms, slightly stronger associations were 
seen. The OR of any GERS was 2.13 (95% CI 1.45-3.13) among individuals exposed in both 
HUNT2 and HUNT3, and 1.54 (95% CI 1.25-1.90) among those exposed in HUNT2 only, 
compared to non-exposed. The corresponding ORs of severe GERS were 5.39 (95% CI 2.83-
10.26) and 2.43 (95% CI 1.53-3.84), respectively. Since the crude ORs were similar to the 
adjusted ORs, only the adjusted ORs are shown (Table 9).
Table 9 Exposure to sleep problems and insomnia symptoms and risk of any and severe
gastroesophageal reflux symptoms (GERS). Odds ratios (OR) with 95% confidence intervals 
(CI) were adjusted for sex, age, body mass index (BMI), tobacco smoking and education1.
Cohort 1
Incidence of any 
GERS3
Incidence of severe 
GERS4
N= 16,7542
Exposure to sleep problems5 OR 95% CI OR 95% CI
No sleep problems (reference) 1.00 - 1.00 -
Sleep problems in HUNT2 but not at 
HUNT3/Mini-Q 1.51 1.23-1.84 2.06 1.26-3.36
Sleep problems at HUNT3 /Mini-q but not in 
HUNT2 1.46 1.28-1.66 2.14 1.57-2.92
Sleep problems at both HUNT2 and 
HUNT3/Mini-Q 1.84 1.48-2.30 3.53 2.28-5.48
Cohort 2
Incidence of any 
GERS3
Incidence of severe 
GERS4
N= 14,9466
Exposure to insomnia7 OR 95% CI OR 95% CI
No insomnia (reference) 1.00 - 1.00 -
Insomnia in HUNT2 but not in HUNT3 1.54 1.25-1.90 2.43 1.53-3.84
Insomnia in HUNT3 but not in HUNT2 1.70 1.40-2.08 2.32 1.48-3.63
Insomnia at both HUNT2 and HUNT3 2.13 1.45-3.13 5.39 2.83-10.26
1The crude ORs were very similar to the adjusted and are therefore not shown.
2The cohort included data from HUNT2, HUNT3/Mini-q without GERS in HUNT2
3Any GERS: minor or severe complaints with heartburn or acid regurgitation
4Severe GERS: severe complaints with heartburn or acid regurgitation 
5Sleep problems were defined as having difficulty falling asleep several times a week
6The cohort included participants in HUNT2 and HUNT3 without insomnia in HUNT2
7Insomnia was defined as having daytime sleepiness/experiencing impaired work performance due to sleep problems and 
having difficulty falling asleep or waking up to early several times a week.
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5.4.3 Any and severe GERS as risk factors for developing sleep problems 
and insomnia symptoms
Between HUNT 2 and HUNT3/Mini-Q, 1,725 participants (8%) developed sleep problems 
and 497 participants (3%) developed insomnia symptoms. Participants with any GERS in 
both HUNT2 and HUNT3/Mini-Q had an odds ratio of 1.91 (95% CI 1.68-2.17) compared to 
those without GERS. For participants exposed to GERS in HUNT2 only there was a 46% 
increased occurrence sleep problems (OR 1.46; 95% CI 1.20-1.78) compared to non-exposed 
(Table10). 
Similar estimates were observed for individuals exposed to severe GERS in HUNT2 and 
HUNT3 (OR 1.92; 95% CI 1.37-2.69) and in HUNT2 only (OR 2.0; 95% CI 1.56-2.56). The 
OR of insomnia symptoms was increased among those exposed to any GERS in HUNT2 and 
HUNT3 (OR 2.15; 95% CI 1.71-2.72) and among those exposed in HUNT2 only (OR 1.51; 
95% CI 1.05-2.16), compared to those without GERS. The risk of insomnia symptoms 
among those exposed to severe GERS in HUNT2 only was more than 2-fold increased (OR 
2.24; 95% CI 1.49-3.69), while the OR was attenuated (OR 1.75; 95% CI 0.94-3.25) among 
those exposed to severe GERS in HUNT2 and HUNT3. Since the crude ORs were similar to 
the adjusted ORs, only the adjusted ORs are shown (Table 10).
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Table 10. Exposure to any and severe gastroesophageal reflux symptoms (GERS) and risk of 
sleep problems and insomnia symptoms. Odds ratios (OR) with 95% confidence intervals 
(CI) were adjusted for sex, age, BMI, smoking and education1.
Cohort 3 N= 21,5002  
 Incident sleep 
problems3 
Exposure to any GERS4 OR 95% CI 
No GERS (reference)  1.00 - 
Any GERS in HUNT2 but not in HUNT3/Mini-Q 1.46 1.20-1.78 
Any GERS in HUNT3 /Mini-Q but not in HUNT2  1.44 1.25-1.65 
Any GERS at both HUNT2 and HUNT3/Mini-q 1.91 1.68-2.17 
Exposure to severe GERS5 
  No severe GERS (reference) 1.00 - 
Severe GERS in HUNT2 but not in HUNT3/Mini-
Q 2.00 1.56-2.56 
Severe GERS in HUNT3 /Mini-Q but not in 
HUNT2 1.94 1.60-2.36 
Severe GERS at both HUNT2 and HUNT3/Mini-
Q 1.92 1.37-2.69 
Cohort 4 N= 18,0256   Incident insomnia7 
Exposure to any GERS4 OR 95% CI 
No GERS (reference) 1.00 - 
Any GERS in HUNT2 but not in HUNT3 1.51 1.05-2.16 
Any GERS in HUNT3 but not in HUNT2 1.67 1.32-2.13 
Any GERS at both HUNT2 and HUNT3 2.15 1.71-2.72 
Exposure to severe GERS5 
  No severe GERS (reference) 1.00 - 
Severe GERS in HUNT2 but not in HUNT3 2.24 1.49-3.69 
Severe GERS in HUNT3 but not in HUNT2 1.90 1.36-2.66 
Severe GERS at both HUNT2 and HUNT3 1.75 0.94-3.25 
1 The crude ORs were very similar to the adjusted and are therefore not shown
2The cohort included participants in HUNT2 and HUNT3/Mini-Q without sleep problems in HUNT2
3 Sleep problems were defined as having difficulty falling asleep several times a week 
4Any GERS: minor or severe complaints with heartburn or acid regurgitation
5Severe GERS: severe complaints with heartburn or acid regurgitation
6The cohort included participants in HUNT2 and HUNT3 without insomnia in HUNT2
7Insomnia was defined as having daytime sleepiness and having difficulty falling asleep or waking up to early several times a 
week.
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6 DISCUSSION
6.1 METHODOLOGICAL CONSIDERATIONS 
All studies included in this thesis are observational epidemiological studies of population-
based design. For a study to be population-based it must have full coverage (at least in 
theory) over the specific population within the area that is being studied. Challenges in 
epidemiological studies include selecting the correct study design for the research question 
and to minimize errors, which can otherwise compromise the interpretation and 
generalizability of the results. There are two main types of errors in epidemiological studies, 
random errors and systematic errors. Random errors (chance) are variability in the data that 
we cannot explain and the impact of these will decrease with increased sample size. 
Systematic errors can be divided into three main types: selection bias, information bias and 
confounding. In contrast to random errors, systematic errors cannot be addressed by 
increasing the sample size, but are related to the design of the study and how the variables are 
measured.105 The ideal epidemiological study, and what is regarded as giving highest quality 
evidence, is a randomized interventional trial. These trials, if performed correctly with a 
sufficiently large sample size, will take care of all confounding as a result of the 
randomization, and therefore findings will be due to the intervention under study. However, it 
is not always feasible or ethical to perform such trials, e.g. when it comes to research 
addressing associations between sleep problems and GERD, and large prospective cohort 
studies are regarded as the preferred observational study design in these cases. 
In the section below, some of the methodological considerations of the studies will be 
discussed, using epidemiological concepts.  
6.1.1 Study I and IV
Study I and IV are both prospective cohort studies with a longitudinal design, which use data 
from 2 time points, i.e. from HUNT2 1995-1997 and HUNT3/Mini-Q 2006-2009. Strengths 
of these datasets include the fact that they are large and represent the whole adult population 
in a well-defined area, i.e. residents of the county of Nord-Trøndelag. However, there was a 
drop in participation from 64% in HUNT2 (including those who reported GERS status) to 
49% in HUNT3/Mini-Q. One of the reasons for the drop in participation in HUNT3 was that 
GERS was assessed in the main postal questionnaire in HUNT2 but in the second 
questionnaire administered at screening stations at HUNT3. This means that some people, 
e.g. those with a busy lifestyle, might be under represented, and analyses of non-participation 
also revealed that “had not time/inconvenient session” was the most common reason for not 
participating in HUNT3. Among the oldest (80+ years), “too ill to participate” was the most 
common reason for non-participation.106 Both in HUNT2 and HUNT3 the participation rates
were lower in younger age groups and among males compared to older age groups and 
females. A lower percentage of participants in Mini-Q reported any GERS (29.1%) compared 
to in HUNT3 (43.1%) and severe GERS (4.3%) compared to in HUNT3 (7.1%). The profile 
of participants in Mini-Q also differed in the sense that they were to a greater extent men 
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(51% compared to 44% in HUNT3), had a lower mean age, (45.9 years compared to 53.4 
years in HUNT3) and lower mean BMI, (26.1% were obese compared to 27.2% in 
HUNT3).107 There might be an overestimation of the occurrence of GERS in HUNT3 which 
might influence results in the parts of study IV where analyses were restricted to HUNT2 and 
HUNT3 only, but less so in study I as the results of Mini-Q and HUNT3 were combined. 
Non-participation of the elderly due to being too ill could theoretically be related to both 
GERS and sleep problems, and selection bias cannot be excluded, but these disorders would 
in most individuals not counteract participation. Moreover, these analyses were limited to 
participants under the age of 80. The relatively large sample size, particularly in study I, 
allowed robust sub-analyses and decreased the risk of chance findings.
There were on average 11 years between the assessments in HUNT2 and HUNT3/Mini-Q. 
Unfortunately, we could not follow participants between these assessments, leaving a risk 
that incident cases of GERS, insomnia and sleep problems might not be true incident cases 
but instead represent recurrent symptoms. Particularly in study IV the ability to measure 
person-years would have been an asset, thus giving us the ability to better measure the 
magnitude of effects.  
In study IV, sleep problems were assessed with the question “Have you had difficulty falling 
asleep during the last month?” while in HUNT3/Mini-Q sleep problems were assessed with 
the question “How often during the last 3 months have you had difficulty falling asleep”. This 
difference in time might introduce information bias due to misclassification. However, there 
is little reason to believe that they would be different among participants with GERD and 
those without GERD.  
6.1.2 Study II 
This study has a nested case-control design which uses a co-twin control method to assess the 
influence of heredity. The study is cross-sectional, which limits what can be inferred from the 
results. Therefore, we cannot say anything about the direction of associations, only that there 
are associations between sleep problems and GERD. In this study only same sex twins that 
were at least 65 years of age at the time of the interview were included. This restriction was 
due to the fact that only this group had answered the sleep questions. This age restriction in 
combination with the request for complete pairs (in the co-twin analyses with discordant DZ 
and MZ pairs) may have selected a group of elderly participants who are healthier (have the 
ability to participate in the interview) and do not have strong heritability for a deadly disease 
that occurs in younger ages. This was partly accounted for by letting an informant perform 
the interview if the twin was not able to participate himself/herself and thereby avoiding 
selection bias.99 Both GERD and sleep problems are common and in older ages,36,108,109 and
symptoms might be more severe among older GERS patients,110 and the results might not be 
generalizable to younger people. On the other hand, the risk of problems with generalizability 
due to the fact that they are twins per se is probably low, and twin studies reveal similar 
results to studies of singlrtons for a number of diseases.111,112 In the analysis of discordant MZ 
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twins we were left with 210 twin pairs, and it cannot be excluded that smaller effects might 
not have been detected due to limited statistical power. 
6.1.3 Study III
Study III has a case-control design and all cases came from the larger Brisbane area, 
Australia and were matched to population controls from the electoral role. Strengths of the 
study include a strict assessment of Barrett´s esophagus cases and reports of new cases of 
Barrett´s from all operating labs in the area. In the process of attaining information from 
patients’ medical records, 44% either declined to be contacted by the researchers or could not 
be contacted before their diagnosis could be confirmed. Of the remaining cases, some were 
found ineligible due to previous diagnoses of Barrett´s, presence of adenocarcinoma of the 
esophagus or having moved out of the area. There was also a time gap between the databases 
SDH and BOMS, during which additional participants were diagnosed with adenocarcinoma 
of the esophagus, were too ill or moved out of the area or could not be contacted. Selection 
bias might have been present in this process and both cases and controls who remained in the 
study and chose to participate might e.g. have been more health conscious and had better diet, 
which might influence the frequency of symptoms of obstructive sleep apnea. There is also 
up to a 7 year time difference between the assessment of Barrett´s esophagus and the 
assessment of daytime sleepiness and sleep apnea symptoms. Changes in diet and exercise 
regime during the time interval, and a consequent decrease in BMI, which in turn has been 
shown to decrease OSA severity,67 could influence the ability to correctly measure the 
association under study. However, a study investigating the association between abdominal 
obesity and Barrett´s esophagus using the same data compared BMI and smoking habits at 
the time of recruitment (close to the Barrett´s assessment) and BOMS assessment found a 
good correlation between measures.59 There are also indications that OSA progresses rather 
than declines in mild to moderate cases over time.67
In study III we did not have the ability to measure clinical OSA, but used the Epworth 
sleepiness scale (ESS) to assess daytime sleepiness and a sleep apnea index to assess 
symptoms of obstructive sleep apnea instead. Both the ESS scale and the sleep apnea 
symptom index have been validated, and have been shown to correlate well with OSA,104,113
but ESS has also been criticized to correlate with symptoms of psychiatric disorders.114 The 
ESS does not measure daytime sleepiness in a defined time period just “in recent time” and a 
person with, e.g. depression might overestimate symptoms. We did not obtain a 
psychological assessment of our cases and controls, but even though there might be a risk of 
misclassification of symptoms of sleep apnea and the daytime sleepiness seen could have 
been due to other causes, it does not seem likely that it would differ between cases and 
controls, i.e. the misclassification should have been non-differential and dilute associations 
rather than increasing them. Such dilution might have contributed to the lack of statistically 
significant findings of this study
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6.2 ETHICAL CONSIDERATIONS
All studies included in this thesis were approved by the relevant regional ethical review 
boards. For study I additional permission to link HUNT2 data with NorDP was obtained from 
the Norwegian Directorate of Health and the Data Inspectorate. This was needed due to the 
fact that at the time of HUNT2, linkage to NorDP was not possible and consent did not 
include this register. Written informed consent was gathered for all participants in HUNT2, 
HUNT3, Mini-Q, SDH and BOMS at the time of the data collections. For the twins 
participating in the SALT- study, interviews were held over the phone and not in person and 
only oral consent could be obtained. Information about the study was sent out prior to the 
interviews informing potential participants about the study, and all twins were sent a letter 
after the study confirming that they had consented and information on who to contact if they 
wished to withdraw consent. No interventions were performed on the participants and the 
risks involved in participating in the studies were perceived as low. To reduce integrity risks 
for participants, all data were kept on safe servers with limited access and without identifiers 
such as names and personal identity numbers.
6.3 FINDINGS AND IMPLEMENTATION OF RESULTS
6.3.1 Study I
In this study we found a substantial (30%) increase in the prevalence of any GERS between 
1995-1997 (31.4%) and 2006-2009 (40.9%). The prevalence of severe GERS increased by 
24%, from 5.4% to 6.7 % and an increase of at least weekly GERS of 47%, from 11.6 % to 
17.1%. The absolute number of individuals with new GERS exceeded the number who lost 
GERS during the study period, even though the estimated annual loss of severe GERS was 
higher (1.22%) than the annual incidence (0.23%). Age had a larger influence on the 
incidence of GERS among women while among men the incidence was more stable with age. 
More young women lost their GERS compared to young men or older participants. This was 
not explained by pregnancy, as exclusion of pregnant women only marginally changed the 
results.
Previous research on population-based prevalence of GERS is heterogeneous which might be 
explained by the variability in definition of GERS between studies. Two American studies 
which used the same source population in 1980s to 1990s found that the prevalence of at least 
weekly heartburn increased from 13.2% (n=835, aged 30-64 years) to 17.8% (n=1,511, age 
25-74 years).115,116 The prevalence of at least weekly acid regurgitation remained however 
stable on 6.5% and 6.3% respectively. A Swedish study found an increase in the prevalence 
of any GERS from 20-21 % in 1986 (n=337, age 20-79 years) to 22-25% at follow-up 10 
years later (n=197).117,118 In contrast to our findings and the studies above, a recent Danish 
study found that the prevalence of at least mild GERS was stable over time, 22% at 1998-
1999 (n= 6781, aged 40-65 years) and at the 5 year follow-up (n=5578).119
47
There are a few studies which have measured GERS at least two periods in time, providing a
possibility to address incidence or loss of GERS. A Danish study with baseline data in 1982-
1984 and follow-up assessment in 1987-1988 (n=2987; aged 30-60 years at baseline) 
reported an annual incidence of any GERS of 13-19% and an annual incidence of frequent 
GERS of 1-3%.120 A Swedish study with baseline in 1988 and 1 year follow-up (n=1059; 
aged 20-79 years at baseline) reported an annual incidence of predominant GERS of 0.05% 
and an annual incidence of GERS with other concurrent gastrointestinal symptoms of 
0.75%.121 An American study from 1988-1991 with 12-20 months of follow-up (n=690; aged 
30-64 years at baseline) reported a cumulative onset rate of heartburn several times a week or 
daily of 2.7%, corresponding to average annual onset rates of 1.6-2.7%.122 In the most recent 
study from Denmark with baseline in 1998-1999 and follow-up 5 years later (n=5578; aged 
40-65 years at baseline), an annual incidence of at least mild GERS of 2.2% was reported.119
Our results are similar to the studies above, with exception of the first Danish study. 
A few studies also measured the loss of GERS. The Danish study from 1982-1984 with 
follow-up in 1987-1988 reported cumulative loss of any GERS of 27-37%, corresponding to 
average annual loss of 6.2-9.0%.120 The cumulative loss of frequent GERS from the same 
study was 59-77%, corresponding to average annual loss of 16.1-23.2%. The US study 
reported cumulative loss of heartburn several times a week or daily of 47.8%, corresponding 
to average annual loss of 36.9-61.3%.122 The Swedish study with 1 year follow-up reported 
an annual loss of any GERS of 1.1-1.3%,117 and the most recent Danish study reported annual 
loss of at least mild GERS of 8.6%.119 These results, with exception of the Swedish study,
deviates from our study, but the large sample size, the ability to adjust for anti-reflux 
medication strengthen the validity of our results. Also, apart from the most recent Danish
study, our study ends in the 21st century and a recent review combining studies of at least 
weekly GERS from North America, East Asia, Europe and the Middle East, showed a
statistically significant trend of higher prevalence numbers after 1995, compared to prior to
1995.1 There might have been lifestyle changes over time that account for the higher 
prevalence seen in more recent years and people might to a higher degree maintain their 
GERS if loss due to antireflux medication is not accounted for.
The increasing prevalence of GERS found in this study may contribute to increasing 
incidence of Barrett´s esophagus and adenocarcinoma of the esophagus. GERD also has a
negative impact on health related quality of life for patients2 and increasing cost for 
medications and health care visits for society.4 Effective treatment and more research 
concerning lifestyle prevention and medication use are needed. 
6.3.2 Study II and study IV
These studies are discussed jointly as they are both investigating the association between 
sleep problems/insomnia symptoms and GERD/GERS. 
In study II we investigated the association between sleep problems and GERD and adjusted 
for genetic and early environmental factors. Results from the external analyses (including all 
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twins) showed doubled occurrence of GERD for “often” having sleep problems (OR 2.0; 
95% CI 1.8-2.4) compared to “seldom” and 50% increased occurrence for “sometimes”
having sleep problem (OR 1.5, 95% CI 1.3-1.7) compared to seldom.  When the results were 
compared with the results of the co-twin within-pair analyses for DZ and MZ twins, the effect 
of “often” having sleep problems compared to “seldom“ having sleep problems (“never” as 
reference) remained for DZ twins, while the effects decreased and become non-significant in 
co-twin analysis with MZ twins. Such decrease among MZ twins indicates genetic influence. 
However, in the cross-trait correlations we found little evidence for genetic influence and the 
decrease in effect for MZ twins can also be due to limited sample size. An exception is the 
association seen for the item “disturbed sleep” which has an increased effect for ”sometimes”
having disturbed sleep  among MZ twins but this could be a chance finding. 
In study IV we found a strongly increased risk of developing GERS among individuals with 
sleep problems, and a moderately increased risk of developing sleep problems among persons 
with GERS. The association between insomnia symptoms and incident severe GERS was 
stronger (OR 5.39; 95% 2.83-10.26, non exposed as reference) than between sleep problems 
and incident any GERS (OR 1.84; 95% CI 1.48-2.30 exposed in both surveys, non-exposed 
as reference), and a longer exposure time (exposed in both surveys) entailed a higher risk 
than if the participant were exposed to sleep problems and insomnia in the first survey only.
In the analyses with GERS as exposure and risk of incident sleep problems/insomnia the 
pattern with higher estimates among participants exposed in both surveys were also seen in 
the analyses with participants exposed to any GERS, but not when exposed to severe GERS.
Furthermore we found a 2-fold association between exposure to any GERS at HUNT2 and 
HUNT3 (non-exposed as reference) and incident insomnia (OR 2.15; 1.71-2.72) while the 
effect for severe GERS (exposed at HUNT2 and HUNT3 compared to non-exposed) and 
incident insomnia symptoms was lower and become non-significant (OR 1.75; 95% CI 0.94-
3.25).
As far as we know, there are no previous twin studies investigating the heritability association 
between sleep problem and GERD. We found little evidence for genetic confounding, but this 
should be investigated in a younger population as well. A clear association between sleep 
problems and GERD has however previously been seen in large epidemiological studies. In a 
population-based cross-sectional case-control study from our group, also using data from the 
Nord-Trøndelag, Norway (HUNT1 and HUNT2) (including 3,153 subjects with severe 
GERS and 40,210 controls), a positive dose-response association between problems falling 
asleep and severe GERS was found. The study also found a strong association between 
insomnia symptoms and severe GERS (OR 3.2; 95% CI 2.7-3.7), when adjusting for age, sex, 
smoking, BMI and education.88 In another population-based study using the 2006 US 
National Health and Wellness Survey (including 11,685 with GERS (at least 2 times per 
month), and 29,643 population controls) found that participants with GERD had a 2-fold 
increased occurrence of sleep difficulties compared to those without GERD (OR 2.09 ; p< 
0.001) and a 75% increased occurrence of sleep induction problems (OR 1.75 <.001).89
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An effect of sleep problems on GERD has also previously been indicated. A recent
longitudinal Chinese study from Hong Kong with a mean 5 year follow-up (185 cases with 
non-restorative sleep at baseline and 2106 participants without) found a clear association 
between non-restorative sleep at baseline and GERD at follow up (OR 2.44, 95% CI 1.33-
4.46) after adjusting for age, gender, education, marital status, family income and regular 
medication use.70 In a randomized clinical trial with crossover design, (including10 cases 
with erosive esophagitis and 10 healthy controls), participants were randomized to sleep 
deprivation (1 night with ≤3 hours of sleep ) or sufficient sleep (3 days with ≥ 7 hours of 
sleep per night) and then after a week’s washout time switched to the other arm.93 The study 
found that following sleep deprivation compared to sufficient sleep, subjects with esophagitis 
had significantly shorter lag time to symptom generation and increase in acid perfusion 
sensitivity score, after stimulus to esophageal acid perfusions. In controls, no difference was
seen and it was suggested that sleep deprivation can enhance esophageal sensitivity to acid in 
patients with GERD and increase GERD symptom severity in sleep deprived patients.93 This 
mechanism might partly explain the findings of study IV, which showed a stronger effect of 
developing GERS in participants with sleep problems, than developing sleep problems in 
participants with GERS. It has previously been suggested that there is a bidirectional 
association between GERD and sleep problem and that sleep disturbances aggravate reflux 
which in turn worsen sleep problem and it then continues as a vicious circle.6
Because of this close link between GERS and sleep problems, combined treatment of these 
disorders might be called for. In an intervention study of primary care patients in Canada (n 
=1.388; 825 reported GERD-related sleep disturbance at baseline) where GERD patients 
were randomized to either PPI or their current treatment, showed that patients with sleep 
disorders  experienced improvement of their sleep problems after the more aggressive PPI 
treatment.123 Sleep medications such as benzodiazepines have on the other hand shown to be 
associated with heartburn during sleep,94 so a choice of different  sleep medications in 
patients with both GERD and sleep problem might be needed. 
6.3.3 Study III 
We hypothesized that OSA would increase the risk of Barrett’s esophagus by increasing the 
intensity of GERD but no statistically significant associations between excessive daytime 
sleepiness, sleep apnea symptoms and Barrett’s esophagus were found. In the last model in 
these analyses we included GERS and the small non-significant risk estimates completely 
disappeared, indicating that any association with Barrett´s esophagus is mediated through 
GERS. We found an association between sleep apnea symptoms and GERS among controls 
which remained after adjusting for BMI.
Only a few studies have previously investigated the potential association between OSA and 
Barrett´s esophagus. In a US study including 54 cases of Barrett’s esophagus and 233
controls (62 upper endoscopy controls and 171 colonoscopy controls), found a 2-fold 
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increased risk of being at high risk for OSA among Barrett´s esophagus patients compared to 
colonoscopy controls (OR 2.08; 95% CI 1.12-3.88).124 However, in the multivariable model 
adjusting for age and BMI, the association was attenuated and become non-significant (OR 
1.51; 95% CI 0.72-3.15). No significant association was found between Barrett’s esophagus 
and risk for OSA compared to upper endoscopy controls (OR 1.73; 95% CI 0.83-3.62). The
Berliner Questionnaire was used to assess the risk of OSA and included questions regarding
snoring, daytime somnolence and obesity/hypertension.124 Another US study, including 7,590
patients from the Mayo Clinic Life Science System and Enterprise Data Trust databases who 
underwent polysomnography and upper endoscopy during a 12-year period, found a 37% 
increased risk of Barrett’s esophagus among OSA patients (OR 1.4, 95% CI 1.1-1.7).125
However, no adjustment for BMI was conducted. In another study from the Mayo Clinic,
using a case-control design, found an 80 % increased occurrence of Barrett´s esophagus 
among patients with OSA (OR 1.8; 95% CI 1.1-3.2) after adjusting for age, sex, BMI, 
smoking history and GERD.126 The sample strategy of the cases and controls of this study can 
however be questioned as they were sampled with a 2:1 ratio from three predefined groups of 
combinations of Barrett´s esophagus and OSA, and thereby sampled both with regards to 
outcome and exposure. The sample left for the analyses then consisted of the four groups of 
confirmed diagnoses: yes Barrett’s and no OSA n=36, no Barrett’s and no OSA n=74, no 
Barrett´s and yes OSA=78, and yes Barrett´s no OSAN=74,126 leaving an already predefined 
ratio between OSA and Barrett´s. The study did however also find an association between 
increased severity of OSA and Barrett´s esophagus (OR 1.2 per 10-unit increase in the apnea-
hypnea index, 95% CI 1.0-1.3) which suggests a true association.126 To further invest this 
association, there is need for larger prospective population-based studies. In our study we did 
not find any statistically significant association between symptoms of OSA and Barrett´s 
esophagus, but an association between at least weekly GERS and symptoms of OSA and 
excessive daytime sleepiness among the controls. This latter association has been found also 
in previous studies,97,127 and treatment with continuous airway pressure (CPAP) of OSA have 
shown to decrease GERS,95 but conflicting results have also been found.128  
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7 CONCLUSIONS
 Between 1995-1997 and 2006-2009 the prevalence of GERS increased substancially. At
lest weekly GERS increased with 47% , from 11.6% to 17.1%. The average annual 
incidence of severe GERS was 0.23% and the corresponding spontaneous loss was 
1.22%. 
 There is a dose-dependent association between sleep problems and GERS that does not 
seem to be confounded by hereditary factors.
 No statistical significant association between obstructive sleep apnea symtoms and 
Barrett´s esophagus were found. If there is an association it is probably mediated by 
GERS.
 The association between sleep problems and incident GERS seems to be bidirectional, 
and sleep problems seems to be a stronger risk factor for GERS than GERS for incident
sleep problems.
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8 FUTURE STUDIES
The association between sleep problems and GERD has been explored in a number of studies 
but there are still gaps to fill. This thesis explored the association by performing a cohort 
study with the ability to measure the cumulative incidence of sleep problems and GERD, but 
incidence measured by risk ratios are sparse. There is information on sleep problems and 
GERD in HUNT2, HUNT3/Mini-Q and in the planned HUNT4 that will be launched in 
2017. NorPD includes all drugs dispensed by prescription in Norway since January 2004. In a 
future study it would be interesting to perform a classical cohort study, with a similar design 
as study IV. HUNT3 could be used as a baseline and time to sleep problem/GERD defined as 
the first prescription of sleep medication/GERD medication could be measured. By counting 
person-years and estimating risk ratios, the magnitude of the GERD sleep association could 
be measured.
In a study performed by our research group using HUNT2 and HUNT3, we found that weight 
loss in combination with GERD medication use gave a 4-fold chance to be free of GERS.45 It 
would be interesting to perform a study addressing changes in weight between HUNT2, 
HUNT3, and HUNT4 and compare it with the usage pattern of GERD medication from 
NorPD. It could also be interesting to adjust the results for sleep problems, as studies have 
found an increased risk of weight gain in people with short sleep duration.129,130
In study III we studied the association of symptoms of OSA and Barrett´s esophagus but an 
important limitation of the study was the lack of clinical assessment of OSA. A recent study 
found an increased risk for Barrett´s esophagus in patients with OSA, but the study had a 
small sample size and methodological issues.126 It would be interesting to perform a large 
register-based study in Sweden on OSA and the risk of Barrett´s esophagus, using data from 
the Patient Register which includes all in-patient care in Sweden since 1987 and also includes 
specialist open care visits since 2001, to study this association further. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING
Gastroesophageal refluxsjukdom innebär ett återflöde av magsäcksinnehåll upp i matstrupen 
och orsakar besvärande symtom i form av halsbränna eller sura uppstötningar. Halsbränna 
och sura uppstötningar är vanligt i befolkningen och i västvärden drabbas i genomsnitt över 
var fjärde person minst en gång i veckan. Refluxsjukdom kan också leda till allvarliga 
följdsjukdomar som matstrupscancer liksom försämrad livskvalitet för den som drabbas och 
höga behandlingskostnader för samhället. Sömnproblem är också ett vanligt hälsoproblem i 
västvärlden och drabbar ungefär en tredjedel av befolkningen. När man mäter sömnproblem 
brukar man fråga efter hur ofta under den senaste månaden/3 månaderna man har haft svårt 
att somna, har haft avbruten sömn med uppvaknanden eller om man vaknar för tidigt och har 
svårt att somna om igen. I flera tidigare studier har man sett ett samband mellan 
sömnproblem och refluxsjukdom och det har föreslagits att det är ett dubbelriktat samband, 
d.v.s. sömnproblem kan leda till refluxsjukdom och refluxsjukdom kan leda till 
sömnproblem. Syftet med den här avhandlingen var att vidare undersöka det här sambandet 
genom att se om det påverkas av ärftliga faktorer och undersöka sambandets riktning. Det 
närliggande sambandet mellan obstruktiv sömnapné och Barretts esofagus (en sjukdom som 
innebär cellförändringar i nedre delen av matstrupen för att bättre tåla magsyra och som 
senare kan utvecklas till matstrupscancer) studerades också.
I den första studien undersöktes förändringar i förekomst över tid, nyinsjuknande och förlust 
av reflux. Vi använde oss av datamaterialet Helseundersøkelsen i Nord-Trøndelag (HUNT) 
som innehåller flera stora enkätundersökningar som skickats ut till alla bofasta invånare över 
19 år i fylket Nord-Trøndelag i Norge. Enkäterna har också kompletterats med 
hälsoundersökningar där bl.a. deltagarnas längd, vikt, och blodtryck mättes. Ungefär 60 000 
personer svarade på HUNT2 (1995-1997) och ungefär 45 000 deltog i HUNT3 och Mini-Q
(en enkät för dem som inte ville medverka i den omfattande enkätundersökningen utan i 
stället svarade på ett kortare frågeformulär) (2006-2009). Ungefär 30 000 personer svarade 
både på HUNT2 och HUNT3 och det är framför allt den kohorten vi använder i både studie I 
och studie IV. I studie I såg vi att förekomsten av reflux ökade mellan 1995-1997 och 2006-
2009. Förekomsten av refluxsymtom minst en gång i veckan ökade med 47 %, från 11.6 % 
till 17.1 %. Ökning av förekomst av symptom sågs hos både kvinnor och män och i alla 
åldersgrupper. Under samma tidsperiod nyinsjuknade i genomsnitt 0.23 % av befolkningen 
årligen i nya allvarliga refluxsymtom medan 1.22% av dem med allvarliga refluxsymtom 
blev av med sina tidigare besvär. Bland dessa ingår inte dem som blev av med sin reflux med 
hjälp av medicinering för denna. 
I den andra studien undersökte vi om sambandet mellan sömnproblem och refluxsjukdom 
som man sett i tidigare studier, kan bero på inverkan av genetiska och tidiga miljöfaktorer 
(som kommer till i moderlivet eller under uppväxten). Bakgrunden till att vi vill undersöka 
detta är att man i tidigare studier även sett att ärftlighet förklarar ca 31-40 % av variationen i 
förutsättningen att få refluxsjukdom och för sömnproblem förklarar ärftlighet för ca 33-44 % 
av variationen i sömnkvalitet och sömnlängd. Vi använde oss av Svenska Tvillingregistret 
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och inkluderade 8,014 tvillingar över 65 år som medverkat i en stor telefonintervju som 
utfördes 1998-2002. Genom att använda sig av tvillingar och jämföra resultatet från en extern 
analys som inkluderade alla tvillingar med resultat från analyser med komletta par 
tvåäggstvillingar och enäggstvillingar, kan man se om ett samband delvis kan förklaras av 
genetiska och/eller miljömässiga faktorer. Vi hittade ett starkt samband mellan sömnproblem 
och refluxsjukdom i analysen som inkluderade alla tvillingarna, ungefär dubbelt så många av 
dem som angav att de ”ofta” hade sömnproblem hade reflux jämfört med dem som ”sällan”
hade sömnproblem. I analyserna med endast tvåäggstvillingar där en tvilling har reflux och 
den andra inte, kvarstod sambandet men i analysen med enäggstvillingar så försvagades det. 
Det var dock endast en liten minskning och i tilläggsanalyser såg vi att det var liten risk för 
att sambandet mellan sömnproblem och refluxsjukdom beror på genetiska faktorer.
I den tredje studien tittade vi på relationen mellan obstruktivt sömnapné symptom och 
Barretts esofagus. Obstruktiv sömnapné innebär att man har andningsstopp under sömnen, 
oftast på grund av att tungan ramlar bak i svalget och täpper till luftvägarna. Det leder till 
syrebrist och mikrouppvaknanden för att återfå syresättningen vilket leder till störd sömn. Det 
har tidigare föreslagits att obstruktiv sömnapné bidrar till ökad nattlig reflux genom att sänka 
trycket i den lägre esofageala sfinktern , vilket underlättar återflöde av magsyra i matstrupen. 
Vår hypotes var att sömnapné ger mer allvarlig reflux vilken i sin tur leder till fler fall av 
Barretts esofagus då exponering för magsyra är en av huvudorsakerna till Barretts esofagus. I 
studien inkluderades 237 fall av Barretts esofagus och 247 populationskontroller (personer 
utan Barretts) i en fall-kontrollstudie från Brisbane, Australien. Studien är en del av en 
tidigare större studie och där fallen av Barretts esofagus identifierades och personer utan 
Barretts från samma region, ålder och kön identifierades från vallängden.  Data till studien 
inkluderade frågeformulär om symptom på obstruktiv sömnapné och refluxsymptom samt 
objektiva mått på bl.a. längd, vikt och nackomfång. Det var fler personer med Barretts som 
också upplevde att de ofta hade sömnapnésymptom (20%) jämfört med 
populationskontrollerna (13%), men vi fann inget betydande statistiskt samband mellan 
symptom på obstruktiv sömnapné och Barrets esofagus. Däremot fann vi ett samband mellan 
refluxsymptom och symptom på obstruktiv sömnapné som också setts i tidigare studier.   
I den fjärde och sista studien försökte vi avgöra om sömnproblem i högre grad orsakar reflux 
än refluxs orsakar sömnproblem. Vi använde oss liksom i studie I av Helseundersøkelsen i 
Nord-Trøndelag (HUNT). Både vid HUNT2 (1995-1997) och vid HUNT3/Mini-Q (2006-
2009) tillfrågades deltagarna om sömnproblem och refluxsymtom. Vi ville se om 
sömnproblem orsakar nya fall av reflux, och om det var någon skillnad i sambandets styrka 
om personen hade haft reflux både vid HUNT2 och HUNT3/Mini-Q eller bara vid ena 
tillfället. För att undersöka det inkluderades endast de som inte hade någon reflux vid första 
mättillfället. För att sedan undersöka hur förekomsten av reflux påverkar nya fall av 
sömnproblem analyserades på samma sätt de som inte haft några sömnproblem vid första 
mättillfället och om det var någon skillnad i sambandets styrka om personen haft reflux vid 
båda tidigare mättillfällena. Utav de 16,754 som inte hade någon reflux i HUNT 2 utvecklade 
4,850 (29%) någon form av refluxsymptom till HUNT3/Mini-q och 396 (2%) allvarliga 
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refluxsymptom. Av de 21 500 utan sömnproblem vid HUNT2 utvecklade 1,725 deltagare 
(8%) sömnproblem and 497 (3%) insomniasymptom. I de statistiska analyserna fann vi ett 
starkare samband mellan sömnproblem och att utveckla reflux än mellan reflux och nya fall 
av sömnproblem. Vi såg också starkare samband mellan insomnia symptom och ”allvarliga
refluxsymptom” än mellan sömnproblem och refluxsymtom samt starkare samband om 
personen haft den andra sjukdomen under längre tid (vid båda mättillfällena). Det tyder på att 
det är ett verkligt samband och inte ett slumpmässigt fynd. Sambandet mellan sömnproblem 
och reflux verkar vara dubbelsidigt, men i den här studien fann vi även ett starkare samband 
mellan sömnproblem och att utveckla reflux än det omvända.
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